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6ABSTRACT
The effects of dexmedetomidine as a sedative and premedicant were studied in healthy
laboratory beagles. Dexmedetomidine, a potent and selective α2-adrenoceptor agonist, is
the active ingredient of medetomidine, a commonly used sedative in animals.
The clinical effects and pharmacokinetics of medetomidine, dexmedetomidine and
levomedetomidine were compared to determine whether dexmedetomidine offers any
benefit over racemic medetomidine. A high dose of levomedetomidine was used to eval-
uate whether it has any pharmacological activity or would influence the sedative and anal-
gesic effects of dexmedetomidine in dogs.  Medetomidine and dexmedetomidine were
compared as premedicants prior to propofol/isoflurane anaesthesia, and the most appro-
priate premedicant dose level was determined. Perianaesthetic effects of intramuscular
dexmedetomidine were studied, including 24-hour Holter monitoring to detect arrhyth-
mias. The suitability of a cold pressor test as a stress stimulus using dogs sedated and pre-
medicated with dexmedetomidine as a model was evaluated.
Dexmedetomidine was at least as safe and effective as the corresponding dose of
medetomidine as a sedative, analgesic and premedicant in laboratory beagles.
Levomedetomidine caused no observable behavioural effects in conscious dogs. However,
it did reduce the sedative and analgesic effects of dexmedetomidine and intensified brady-
cardia, suggesting that dexmedetomidine might be preferable instead of medetomidine
for use in dogs. The pharmacokinetics of dexmedetomidine and racemic medetomidine
were similar, but clearance of levomedetomidine was more rapid than that of the other
drugs. A dose of 2 µg/kg of dexmedetomidine resulted in the most stable cardiovascular
effects when used as a premedicant before propofol/isoflurane anaesthesia. After
dexmedetomidine premedication, propofol/isoflurane anaesthesia was considered more
useful than propofol infusion due to a milder degree of respiratory depression and faster
recovery. The cold pressor test produced variable responses among the dogs and was not
a reliable stress stimulus with the dexmedetomidine dose used. In beagles treated with
dexmedetomidine alone or in combination with propofol infusion or propofol/isoflurane,
ventricular arrhythmias were detected no more frequently than in healthy non-anaes-
thetized dogs.
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ACTH adrenocorticotrophic hormone
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AV atrioventricular
cAMP cyclic adenosine 3’, 5’-monophosphate
cGMP cyclic guanosine 3’, 5’-monophosphate
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91. INTRODUCTION
Medetomidine is a potent and selective α2-adrenoceptor agonist that contains equal parts
of two optical enantiomers, dexmedetomidine and levomedetomidine. Enantiomers are
isomers which are mirror images of each other, but in biological systems they may show
differences in pharmacological activity and drug distribution in the body. 
Medetomidine is used as a sedative, analgesic and anaesthetic premedication in ani-
mals, primarily in dogs and cats. It rapidly produces dose-dependent and reliable sedation
and analgesia with good muscle relaxation. Potent anaesthetic-sparing effects of medeto-
midine allow the use of lower doses of anaesthetics as a part of balanced anaesthesia.
Perioperative relief of pain and stress is another valuable property of medetomidine. If
needed, the effects can be antagonized with a specific antagonist, atipamezole. 
Dexmedetomidine, as the active ingredient of the racemic mixture, has gained more
interest than the racemate medetomidine in human anaesthesiology. In intensive care
patients, dexmedetomidine is used to achieve sedation without respiratory depression, and
cardiac patients may benefit from the perioperative cardiovascular stability it induces.
Dexmedetomidine has also been studied in dogs, and its clinical effects are presumed to
be comparable with those of racemic medetomidine. 
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2. REVIEW OF THE LITERATURE
2.1 α-adrenergic receptors 
Adrenergic receptors α and β mediate the actions of noradrenaline and adrenaline. The α-
adrenergic receptors are divided into α1 and α2 types according to differential agonist and
antagonist affinities.  Most α1-adrenoceptors are located postsynaptically, while α2-adreno-
ceptors are found in various neuronal and nonneuronal sites. The activation of α1-adreno-
ceptors results in the release of noradrenaline, whereas α2-adrenoceptor activation inhibits
noradrenaline release from sympathetic nerve terminals (Langer, 1981). Both receptors play
a significant role in the regulation of vascular tone and arterial blood pressure, but their
relative contribution to the balance of vasoconstriction and vasodilatation varies between
animal species (Piascik et al., 1996). 
2.2 α2-adrenergic receptors
The α2-adrenergic receptor is a protein structure that is able to bind to extracellular ligands
of endogenous hormones or exogenous drugs. When an agonist binds to a α2-adrenergic
receptor, the structure of the receptor changes, resulting in coupling with G-proteins (gua-
nine nucleotide binding proteins) (Figure 1). Transmembrane signalling is promoted by the
replacement of guanosine diphosphate (GDP) with guanosine triphosphate (GTP).
Activated receptors inhibit adenylyl cyclase, resulting in a decrease in the accumulation of
intracellular cyclic adenosine 3’, 5’-monophosphate (cAMP), thus attenuating phosphory-
lation of target regulatory proteins. Efflux of K+ through an activated channel causes hyper-
polarization, and neuronal firing is suppressed. Ca2+ entry into the nerve terminals is also
reduced by α2-adrenoceptor stimulation, which may in turn be responsible for its inhibito-
ry effect on secretion of neurotransmitters (Hayashi & Maze, 1993; Piascik et al., 1996;
Khan et al., 1999b).
α2-adrenergic receptors are divided into the pharmacologically different subtypes α2A,
α2B and α2C. In the central nervous system (CNS), α2A is the prevalent subtype, and the
major noradrenergic nucleus in the brain stem, locus coeruleus, contains only subtype α2A
(MacDonald & Scheinin, 1995). Species differences in distribution of subtypes may exist
(Maze & Fujinaga, 2000).
The α2A-adrenoceptor most likely regulates the release of neurotransmitters from nor-
adrenergic neurones (MacDonald & Scheinin, 1995). In genetically modified mouse lines,
α2A-adrenoceptor has been shown to be the predominant subtype involved in the media-
tion of the antinociceptive, sedative, anaesthetic-sparing and hypothermic actions of
dexmedetomidine (Hunter et al., 1997; Lakhlani et al., 1997). The α2A-adrenoceptor sub-
type also appears to have a critical role in the hypotensive response to α2-adrenoceptor
agonists, despite data implicating a role for independent imidazoline binding sites in this
response (MacMillan et al., 1996). Moreover, it is considered the primary mediator of α2-
adrenoceptor-mediated spinal analgesia (Stone et al., 1997; Guo et al., 1999), being nec-
essary for analgesic synergy with opioids (Stone et al., 1997). 
The α2B-adrenoceptor mediates the major component of the immediate hypertensive
action and counteracts the hypotensive action of α2A-receptors. In mice devoid of α2B-recep-
tors, the hypotensive effect occurred immediately and was of greater magnitude than in
normal mice, but the bradycardic response was similar (Link et al., 1996).
The α2C-adrenoceptor contributes to spinal analgesia, adrenergic-opioid synergy
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(Fairbanks et al., 2002), hypothermic action and modulation of dopaminergic activity
(Sallinen et al., 1997) but seemingly produces no haemodynamic effects (Link et al., 1996).
Dexmedetomidine inhibits the release of noradrenaline at the sympathetic innervation of
kidney cortex via activation of α2C-adrenoceptors (Taoda et al., 2001).
Subtype-selective drugs suitable for in vivo use are still non-existent (Schwartz & Clark,
1998; Kamibayashi & Maze, 2000), although some evidence of subtype selectivity of
dexmedetomidine in vitro has been shown (Jansson et al., 1994; Peltonen et al., 1998). 
Figure 1
G-protein-coupled receptor and activation of adenylyl cyclase.
1) The adrenergic agonist binds to the receptor, activating binding of the Gs protein; 2) The Gs-pro-
tein releases GDP and binds GTP; 3) The Gs-protein splits into βγ and αs units, which activates adeny-
lyl cyclase; 4) Production of cyclic AMP (cAMP) is enhanced; 5) GTPase hydrolyses GTP into GDP,
releasing αs from adenylyl cyclase; 6) αs combines with the βγ unit to form the G- protein. In the case
of α2-adrenergic agonists, Gi-proteins (instead of Gs above) inactivate adenylyl cyclase.
Modified from http://perth.uwlax.edu/faculty/howard/MCATreview1/sld031.htm
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2.3 Imidazoline receptors
Some effects of α2-adrenergic agonists may be due to their binding and action in the non-
adrenergic imidazoline (imidazole) receptors. The physiological function of imidazoline
receptors is controversial, but at least the hypotensive effect of α2-adrenoceptor agonists
may in part be mediated by these receptors in the ventral medulla (Ernsberger et al., 1990;
MacDonald & Scheinin, 1995; McCallum et al., 1998). Presumably, they also play a role in
the protection against adrenaline-induced arrhythmias (Hayashi et al., 1993; Khan et al.,
1999b).  
2.4 Dexmedetomidine
Dexmedetomidine, (+) -4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole (Figure 2), is a selec-
tive and potent α2-adrenergic agonist. The α2/α1 selectivity of dexmedetomidine is sever-
al times higher than that of clonidine, detomidine or xylazine (Virtanen et al., 1988; Aantaa
et al., 1993). Dexmedetomidine is therefore considered a full agonist of the α2-adreno-
ceptor, and clonidine a partial agonist. More potent sedation and analgesia with minor car-
diovascular depression from α1-adrenoceptor activation can be expected as a result of full
agonism.
Dexmedetomidine contains an imidazole in its chemical structure and has an affinity
for imidazoline receptors, despite weaker than that for α2-adrenoceptors (Wikberg et al.,
1991; Khan et al., 1999b). 
2.4.1 Cardiovascular effects of dexmedetomidine
The cardiovascular effects of dexmedetomidine have been studied extensively in animals
and humans but are not yet fully understood. Species-specific differences, particularly
between humans and dogs, appear to exist in haemodynamic response to α2-adreno-
ceptor agonists (Flacke et al., 1990, 1993; Bloor et al., 1992b; Ebert et al., 2000).
Figure 2
Structure of the medetomidine enantiomers.
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Peripheral α-adrenoceptors mediate vascular contraction by regulating calcium influx.
After administration of dexmedetomidine, an initial pressor response is produced via vaso-
constriction, followed by a secondary baroreflex-mediated decrease in heart rate. Systemic
vascular resistance is increased and cardiac output is decreased. Bradycardia is subse-
quently produced mainly via diminished sympathetic (Schmeling et al., 1991; Xu et al.,
1998; Hogue et al., 2002) and/or augmented parasympathetic tone (Bloor et al., 1992b),
and blood pressure declines gradually to or beyond baseline level (Bloor et al., 1992a,
1992b). The site of central control of blood pressure is suggested to be the rostral ven-
trolateral medulla (Hong et al., 1992). Despite later hypotension, heart rate does not
increase, which suggests an inhibitory effect on the baroreflex or resetting of the barore-
flex (Xu et al., 1998). In humans, baroreflex sensitivity was unaffected while systemic sym-
pathetic tone was reduced by dexmedetomidine (Hogue et al., 2002). Dogs may exhibit
a more profound vasoconstrictive response to α2-adrenoceptor agonists than humans, as
indicated by a greater degree of systemic vascular resistance and a lesser degree of sub-
sequent hypotension after dexmedetomidine administration (Flacke et al., 1990; Bloor et
al., 1992, 1992b). However, in humans dexmedetomidine doses are much smaller than
those commonly used in dogs. In a stepwise infusion study, the highest achieved plasma
concentration of dexmedetomidine in human volunteers was 14.7 ± 0.78 ng/ml, result-
ing in distinct increases in arterial pressures and systemic vascular resistance with decreas-
es in heart rate, stroke volume and cardiac output. At the lower (clinically used) plasma
concentrations arterial pressures decreased with less effect on the other cardiovascular
parameters (Ebert et al., 2000). Increasing doses of dexmedetomidine (up to 0.6 ng/ml)
increased blood pressure in anaesthetized volunteers and decreased it in awake subjects
(Talke et al., 2003), showing the effect of baseline sympathetic tone in dexmedetomidine
studies. A peripherally active α2-adrenoceptor antagonist was shown to prevent the
immediate pressor effects of dexmedetomidine but to preserve the majority of the late
cardiovascular effects in dogs (Pagel et al., 1998b). In addition to species and dosing dif-
ferences, the magnitude of hypertension is influenced by the administering method of
dexmedetomidine. Intramuscular (im) injection generally results in less abrupt changes in
blood pressure, and a slow infusion rate may be preferable to a bolus intravenous (iv)
administration (Dyck et al., 1993). 
Dexmedetomidine has been found to depress cardiac function in dogs even after auto-
nomic denervation (Flacke et al., 1990). Postsynaptic α2-adrenoceptors are considered non-
existent in the mammalian heart (Dukes & Vaughan Williams, 1984; Hayashi et al., 1991),
and dexmedetomidine has shown no direct depressant effect on the canine myocardium
(Flacke et al., 1992). Schmeling et al. (1991) interpreted the depression in heart function
caused by dexmedetomidine to be the result of increased arterial pressure, but in isolated
canine hearts, dexmedetomidine-induced increased afterload did not impair cardiac func-
tion (Flacke et al., 1992). In a later study, Flacke et al. (1993) reported diastolic dysfunc-
tion and a decline in systolic contractility in conjunction with decreasing catecholamine lev-
els after dexmedetomidine administration. When haemodynamic changes were antago-
nized by a calcium channel blocker, cardiac function was nevertheless reduced after
dexmedetomidine administration in dogs, probably due to sympatholysis (Roekaerts et al.,
1997). 
The decrease in cardiac output after dexmedetomidine is caused mainly by a decrease
in heart rate. While the increase in blood pressure and the decrease in cardiac output occur
simultaneously, the latter seems not to be completely mediated reflexly (Flacke et al., 1990).
Reduced stroke volume, increased afterload, reduced metabolic demands (Bloor et al.,
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1992b; Ebert et al., 2000), low catecholamine levels and coronary vasoconstriction (Flacke
et al., 1990; Bloor et al., 1992b) have been suspected to contribute to the reduction in
cardiac output. The pressor response to iv dexmedetomidine was enhanced after auto-
nomic denervation (Flacke et al., 1990; Schmeling et al., 1991), but cardiac output
decreased without a change in heart rate (Flacke et al., 1990). Likewise, when bradycar-
dia was blocked by glycopyrrolate pretreatment, the decrease in cardiac output was only
partially reversed, but arterial pressure increased further (Bloor et al., 1992b). Iv dexmedeto-
midine (Lawrence et al.,1996a) and im medetomidine (Pypendop & Verstegen, 2000) have
been shown to considerably redistribute cardiac output in dogs, reducing blood flow to
less vital organs and preserving it in vital organs to levels above those known to induce
underperfusion.
Iv dexmedetomidine has been shown to induce coronary vasoconstriction in dogs
(Schmeling et al., 1991; Flacke et al., 1993). However, in canine myocardial ischaemia
models, iv dexmedetomidine preserved endocardial perfusion and decreased myocardial
oxygen demand, thereby reducing oxygen deficiency of the ischaemic myocardium
(Lawrence et al., 1996b; Roekaerts et al., 1996; Willigers et al., 2003). In pigs, large iv dos-
es of dexmedetomidine caused moderate regional coronary vasoconstriction without meta-
bolic signs of myocardial ischaemia (Jalonen et al., 1995). In goats, the cardiovascular
response to iv dexmedetomidine was found to be similar to that of man; systemic and
coronary vasoconstriction was short-lived, and the balance between myocardial oxygen
supply and demand was maintained (Lawrence et al., 1997). 
2.4.1.1 Cardiovascular effects of dexmedetomidine in humans
Blood pressure was reduced after iv dexmedetomidine (≤1 µg/kg) by 10% to 20% and
heart rate usually decreased moderately (Kallio et al., 1989; Aantaa et al., 1990a, 1990b;
Aantaa 1991a; Jaakola et al., 1991; Jaakola, 1994). Iv dexmedetomidine (0.25 to 2.0
µg/kg) produced a transient increase in blood pressure and a longer lasting decrease in
blood pressure, heart rate and cardiac output (Bloor et al., 1992a).
Im administration of dexmedetomidine (2 µg/kg) avoided the acute haemodynamic
changes seen with iv administration but led to similar haemodynamics within four hours
(Dyck et al., 1993). Preoperative im dexmedetomidine (<1.5 µg/kg) resulted in a lower
heart rate and blood pressure than placebo during thiopentone anaesthesia (Aantaa
1991b). Im dexmedetomidine (1.5 µg/kg) decreased blood pressure 22% and heart rate
by 32% in healthy volunteers, with no signs of initial increase in blood pressure. The
hypotension was still present after six hours when all signs of sedation had disappeared
(Scheinin H et al., 1992). In elderly patients, im dexmedetomidine (1 µg/kg) induced a
moderate decrease in blood pressure and a slight decrease in heart rate (Virkkilä et al.,
1994).  
Infusion of dexmedetomidine (0.2 or 0.6 µg/kg/h) into healthy volunteers resulted in
minor changes in cardiovascular parameters (Hall et al., 2000), and postoperative increas-
es in heart rate and blood pressure were attenuated without significant bradycardia or
hypotension (Talke et al., 1997). Increasing concentrations of dexmedetomidine (from 0.7
to 14.7 ng/ml) resulted in progressive decreases in heart rate and cardiac output, with a
maximal decrease in heart rate of 29% (Ebert et al., 2000). In one case, intraoperative infu-
sion of dexmedetomidine (0.3 µg/kg/h) resolved tachycardia, which had been unrespon-
sive to beta-adrenergic blocker therapy (Ruesch & Levy, 2002).
ECG abnormalities related to dexmedetomidine other than sinus bradycardia have
been rarely reported in humans. After iv dexmedetomidine was administered to 28 healthy
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males, one event of a R-R interval lasting 2.4 seconds and two episodes of junctional
escape rhythm were detected (Bloor et al., 1992a). A sinus arrest and a symptomatic brady-
cardia resulting in loss of consciousness were detected in one out of 15 patients receiving
iv dexmedetomidine, but atropine normalized the heart rate (Jaakola, 1994). One patient
out of 22 receiving dexmedetomidine infusion at plasma concentration of 0.32-0.35 ng/ml
had a long sinus pause during intubation (Talke et al., 2000). 
2.4.1.2 Cardiovascular effects of dexmedetomidine in dogs
In conscious dogs iv dexmedetomidine 1.25 µg/kg increased arterial pressure by 15% and
decreased heart rate by 26% and cardiac output by 35% (Schmeling et al., 1991). Under
isoflurane anaesthesia iv dexmedetomidine 20 µg/kg increased arterial pressure by 67%,
concomitantly decreasing heart rate by 53% and cardiac output by 74%. Arterial blood
pressure remained at least 20% above baseline (under anaesthesia), while heart rate was
40% lower than baseline throughout the four-hour study (Bloor et al., 1992b). Iv
dexmedetomidine 10 µg/kg reduced cardiac output by 50% in anaesthetized dogs. Blood
flow through skin decreased by 70% to 90% and renal flow by 30%, but cerebral and car-
diac blood flows were less affected. Arterial lactate concentrations were unchanged after
dexmedetomidine, implying overall adequacy of oxygen supply to the body (Lawrence et
al., 1996a). In dogs premedicated with fentanyl, iv dexmedetomidine 10 µg/kg decreased
heart rate by 39%, cardiac output by 64% and heart contractility by 29% and increased
mean arterial pressure by 55% as compared with baseline (Roekaerts et al., 1997).
Iv dexmedetomidine induced greater reductions in cardiac output in dogs with dilat-
ed cardiomyopathy compared with healthy dogs (Pagel et al., 1998a).
The cardiovascular effects of iv racemic medetomidine were fully established with dos-
es as low as 5 µ/kg, and increasing the dose prolonged the effects (Pypendop & Verstegen,
1998). Lombard et al. (1989) studied the effects of im medetomidine in dogs with com-
pensated mitral regurgitation and considered the drug to be safe but recommended the
use of an antagonist to reverse cardiovascular effects. The use of anticholinergic drugs aim-
ing to reduce the bradycardia caused by medetomidine is usually not advised, as it may
result in prolonged, severe hypertension leading to increased myocardial oxygen demand
(Vainio & Palmu, 1989; Short, 1991; Alibhai et al., 1996).   
Besides bradycardia, accentuated sinus arrhythmia and sinoatrial and atrioventricular
(AV) heart blocks are the most commonly described arrhythmogenic effects of α2-adren-
ergic agonist drugs in dogs. AV-blocks (first and second degree) develop as disturbances
in the conductivity of the cardiac excitatory impulse. The appearance of AV-blocks after
dexmedetomidine administration has not been reported. Iv and im medetomidine has been
shown to induce occasional second-degree AV-blocks in dogs (Lombard et al., 1989; Vainio
& Palmu, 1989; Ewing et al., 1993; Kramer et al., 1996).
Infusion of dexmedetomidine 0.5 µg/kg/min has been demonstrated to prevent adren-
aline-induced arrhythmias in halothane-anaesthetized dogs in a dose-dependent manner.
The effect appeared to be mediated at least in part by stimulation of central α2-adreno-
ceptors and to be independent of changes in haemodynamic parameters (Hayashi et al.,
1991). In a later study, however, the same authors describe imidazoline-preferring recep-
tors rather than the α2-adrenergic receptor as being responsible for the anti-arrhythmic
property of dexmedetomidine. Activation of the imidazoline-preferring receptors presum-
ably increases vagal tone, which may protect against adrenaline-induced arrhythmias
(Hayashi et al., 1993). In vagotomized or atropine-treated animals, the anti-arrhythmic
effect of dexmedetomidine is abolished (Kamibayashi et al., 1995a). The site of the anti-
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arrhythmic action may be the nucleus reticularis lateralis in the ventrolateral medulla, which
is rich in imidazoline receptors and functionally connected to the area that modulates vagal
activity (Kamibayashi et al., 1995b).
2.4.2 Respiratory effects of dexmedetomidine 
The ventilatory effect of dexmedetomidine in humans resembles that of normal non-REM
sleep, and its impact on central breathing control seems to be minor (Belleville et al., 1992).
Similarly, in dogs, respiratory depression and the effect on hypoxic reflexes caused by
dexmedetomidine are relatively mild, but species-specific variations may exist (Nguyen et
al., 1992). In rabbits, iv dexmedetomidine produced hypercarbia and hypoxia (Zornow,
1991). In sheep, marked hypoxia may develop after iv and im medetomidine or
dexmedetomidine (Raekallio et al., 1998; Kästner et al., 2001a; Kästner et al. 2001b), prob-
ably due to pulmonary venospasm-induced alveolar oedema (Bacon et al., 1998).  
2.4.2.1 Respiratory effects of dexmedetomidine in humans
In healthy humans breathing room air, iv dexmedetomidine (≤2.0 µg/kg) caused a mild
increase in resting arterial blood carbon dioxide tension (paCO2) and a decrease in minute
ventilation with little change in respiratory rate, and arterial blood oxygen tension (paO2)
remained unchanged. Oxygen consumption increased transiently and then decreased.
(Belleville et al., 1992). Partial respiratory obstruction after iv dexmedetomidine (2 µg/kg)
was observed in some patients (Lawrence & DeLange, 1997). Arterial oxygen saturation
was normal after iv and im dexmedetomidine (Jaakola et al., 1991; Jaakola 1994; Bührer
et al., 1994; Talke et al., 1995; Venn et al., 1999). Infusion of dexmedetomidine into
healthy volunteers or surgical patients requiring intensive care resulted in minor respirato-
ry changes, which were not considered to be clinically significant (Hall et al., 2000; Venn
et al., 2000). The mild respiratory depression observed was deemed to be secondary to
profound sedation (Ebert et al., 2000).
2.4.2.2 Respiratory effects of dexmedetomidine in dogs
After administration of dexmedetomidine or medetomidine iv or im, respiratory rate usu-
ally decreases with minimal effects on blood gas values (Vainio 1989; Schmeling et al.,
1991; Venugopalan et al., 1994; Kramer et al., 1996). Nguyen et al. (1992) found that at
low iv dexmedetomidine doses ventilation decreased, but at doses exceeding 20 µg/kg
end-tidal CO2 decreased and end-tidal O2 increased as compared with awake control val-
ues. The authors suggested that this effect might be partially related to the central α1-
adrenoceptor agonist. However, iv dexmedetomidine has been shown to dose-depend-
ently reduce the response to hypercapnia (Nguyen et al., 1992; Sabbe et al., 1994). On the
other hand, a combination of iv dexmedetomidine (Nguyen et al., 1992) or medetomidine
infusion (Bloor et al., 1989) and isoflurane resulted in less respiratory depression than with
isoflurane alone at the same anaesthesia level.
2.4.3 Sedative/hypnotic and MAC-sparing effects of
dexmedetomidine
Several reasons exist for dexmedetomidine being advocated as a sedative agent in human
medicine. It has a relatively short half-life, which enables the use of a continuous infusion.
Sedation and anxiolysis are accompanied by analgesic properties, and under suitable dos-
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ing, the patients are readily roused. Minor respiratory effects, stabilizing cardiovascular
effects and the availability of a specific antagonist are additional advantages (Hall et al.,
2000).
The site of the sedative/hypnotic action of dexmedetomidine resides in the brain stem,
in the locus coeruleus, which controls vigilance and modulates sympathetic outflow
(Correa-Sales et al., 1992a). In rats depleted of catecholamine stores, intraperitoneal (ip)
dexmedetomidine still reduced the minimal alveolar concentration (MAC) of halothane
(Segal et al., 1988); thus sympatholysis alone does not explain the MAC-sparing effect of
dexmedetomidine. The hypnotic action is mediated by inhibition of adenylate cyclase,
which alters phosphoryrylation of the potassium channel (Correa-Sales et al., 1992b).
Dexmedetomidine has shown strong synergistic interactions with gamma-aminobutyric
acid (GABA)-acting compounds, such as midazolam (Salonen et al., 1992), and has been
suggested to partly exert its hypnotic action via GABAergic pathways (Seidel et al., 1995).
It may also be associated with a decrease in serotoninergic neurotransmission and was
demonstrated to be diminished by serotoninergic stimulation in rats (Rabin et al., 1996a).
Decreased glutamatergic neurotransmission, secondary to reduced availability of glutamine
has recently been reported to be involved both in sedative/hypnotic- and anaesthetic-spar-
ing effects of dexmedetomidine (Huang & Hertz, 2000). The nitric oxide/cGMP pathway,
a major signalling transduction pathway implicated in mechanisms mediating conscious-
ness and pain, seems to be an important mediator of the anaesthetic action of dexmedeto-
midine (Vulliemoz et al., 1996; Tonner et al., 1999). When halothane and dexmedetomi-
dine were given simultaneously to mice, the decrease in cerebellar cGMP was greater than
with either of the drugs alone (Vulliemoz, 1998). Buttermann et al. (1998) suggested that
dexmedetomidine produces its anaesthetic effects through different neuroanatomic path-
ways than volatile anaesthetics. In a study made with tadpoles, dexmedetomidine did not
adhere to the Meyer-Overton rule (correlation of lipid solubility with the anaesthetic poten-
cy), implicating a more specific site of action than general anaesthetics. However, the
anaesthetic action of dexmedetomidine was diminished by increased pressures, demon-
strating a similar effect compared with other general anaesthetics, such as barbiturates or
propofol (Tonner et al., 1997).
Dexmedetomidine has been shown to bind to and activate α1-adrenoceptors. Central
α1-adrenoceptor stimulation has been reported to functionally antagonize the hypnotic
response to dexmedetomidine by either a specific or a non-specific interaction between
the receptors (Doze et al., 1989b; Guo et al., 1991; Schwinn et al., 1991) outside of the
locus coeruleus (Correa-Sales et al., 1992a). The transmembrane components involved in
the signal transduction mechanism are different for α1- and α2-adrenoceptors, but these
mechanisms may interact. Pharmacokinetic interaction was considered unlikely, as only a
centrally active α1-adrenoceptor agonist reduced the hypnotic effect of dexmedetomidine
(Guo et al., 1991).
Chronic treatment with tricyclic antidepressant desipramine desensitized rats to the
hypnotic, analgesic, and MAC-reducing properties of dexmedetomidine. Desipramine was
suggested to up-regulate α1-adrenoceptors, causing hyper-responsiveness and thus induc-
ing the normally weak α1-adrenoceptor activity of dexmedetomidine to antagonize its α2-
adrenoceptor-mediated effects. The most vulnerable was the response with the least effi-
cacy (hypnosis) (Guo et al., 1998). Only 4% of α2-adrenoceptors are required for the cen-
tral noradrenaline turnover suppressant effect of dexmedetomidine, while MAC-reducing
action requires >20%, antinociceptive effect >40% and hypnotic effect >80% of the avail-
able α2-adrenoceptors (Hayashi et al., 1995; Rabin et al., 1996b; Guo et al., 1998).
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Tolerance does not develop for either the sympatholytic or MAC-sparing action of
dexmedetomidine after chronic administration, although it does occur for the hypnotic
response (Reid et al., 1994; Rabin et al., 1996b). The most efficient responses have a built-
in reserve that sustains the response even when the transduction mechanism is disrupted
(Rabin et al., 1996b). Thus, the analgesic properties of dexmedetomidine can persist after
the hypnotic response has been attenuated by chronic administration, and animals toler-
ant of the hypnotic and analgesic actions of dexmedetomidine are still capable of exhibit-
ing MAC-sparing action (Hayashi et al., 1995b). The transduction pathway for analgesia
may be more efficiently coupled than that for hypnotic action. Drugs with high intrinsic
efficacy require fewer receptors to exert a pharmacological action; clonidine needs 30%
more receptors for the analgesic effect than dexmedetomidine, and thus, dexmedetomi-
dine is less susceptible to the development of tolerance (Hayashi et al., 1995a). 
In rats, dexmedetomidine caused a slow-frequency, low-amplitude EEG, similar to that
seen in slow-wave sleep. Sleep was disturbed after dexmedetomidine sedation, followed
by increased wakefulness, representing a down-regulation of α2-adrenoceptors or a dis-
ruption in the mechanism that regulates sleep. Imidazoline receptors may also play a role
in the sleep-regulating action of dexmedetomidine (Seidel et al., 1995). 
2.4.3.1 Sedative effects of dexmedetomidine in humans
Dose-dependent sedation was observed at iv doses of 0.5 and 1.0 µg/kg (Aantaa 1991a),
and significant sedation lasted for three hours after a dose of 2.0 µg/kg (Belleville et al.,
1992). Im dexmedetomidine 2.4 µg/kg induced significant sedation and anxiolysis, but
patients were responsive (Aho et al., 1992b). Most subjects fell asleep after 1.5 µg/kg im
dexmedetomidine but were easily roused, and no signs of sedation were seen after six
hours (Scheinin H et al., 1992). 
During infusion of dexmedetomidine (<0.6 µg/kg/h) volunteers could be easily roused
with verbal or physical stimuli (Hall et al., 2000). At a plasma dexmedetomidine concen-
tration of 0.5 ng/ml, patients were heavily sedated and some of them were only roused
by painful stimulation (Bührer et al., 1994). Plasma dexmedetomidine concentration from
1.9 to 14.7 ng/ml produced deep sedation with memory impairment, and at the higher
concentrations the volunteers were unresponsive to loud verbal stimuli and shaking (Ebert
et al., 2000). In patients requiring intensive care, dexmedetomidine (<0.7 µg/kg/h) was
considered a useful agent for the provision of postoperative analgesia and sedation and
for reducing morphine requirements (Venn et al., 1999; Triltsch et al., 2002). The patients
were easily and calmly roused from sleep to allow communication and co-operation while
intubated and ventilated, and then quickly returned to sleep (Venn et al., 1999).
Haemodynamic stability was better maintained in intensive care patients receiving
dexmedetomidine infusion than in those receiving propofol for sedation (Venn et al., 2001;
Triltsch et al., 2002). Interleukin 6 concentration decreased in patients receiving
dexmedetomidine infusion, suggesting a beneficial effect on the inflammatory response
to surgical trauma (Venn et al., 2001).
2.4.3.2 Sedative effects of dexmedetomidine in animals
Dexmedetomidine has usually been studied in anaesthetized dogs, and the sedative effects
of dexmedetomidine in conscious dogs are rarely reported. Iv dexmedetomidine (1 to10
µg/kg) has resulted in dose-dependent sedation in dogs (Sabbe et al., 1994). Racemic im
medetomidine has been shown to produce dose-dependent sedation in dogs at doses up
to 80 mg/kg (Vainio, 1989). The duration of sedation with medetomidine is dependent on
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the dose and route of administration (Vainio, 1989; England & Clarke, 1989; Kramer et
al., 1996). In experimental dogs, sedation was observed even at a dose of 1 µg/kg of iv
medetomidine (Pypendop & Verstegen, 1998). As with other sedatives, a quiet atmosphere
after medetomidine administration is required to maximize the drug’s effects (Kramer et
al., 1996).
Rats were reported to be dose-dependently sedated at subcutaneous (sc) dexmedeto-
midine doses of 30 to 300 µg/kg (MacDonald et al., 1991), but at 1000 µg/kg (ip or sc)
the level of sedation decreased and evidence of excitation was observed (Doze et al.,
1989a; MacDonald et al., 1991; Savola & Virtanen, 1991). Prazosin (an α1-antagonist)
blocked this reversal of sedation. Sc dexmedetomidine 10 mg/kg was a toxic dose to rats
causing pulmonary oedema (MacDonald et al., 1991).
2.4.4 Analgesic effects of dexmedetomidine
While the sedative action of dexmedetomidine is mediated at a supraspinal level, the anal-
gesic response is mainly mediated spinally (Hayashi et al., 1995b). A direct action on the
locus coeruleus may also be implicated, resulting in activation of α2-adrenoceptors in the
spinal cord through which the antinociceptive effect is mediated (Guo et al., 1996).
Pertovaara et al. (1991) suggested that at low doses of medetomidine a supraspinal mech-
anism is involved, and at higher doses antinociception is more spinally mediated.
The direct spinal component of analgesia induced by dexmedetomidine has been stud-
ied in isolated rat spinal cords (Kendig et al., 1991; Savola et al., 1991b). Dexmedetomidine
acted in the dorsal horn of the spinal cord by interrupting the nociceptive pathway to the
ventral root, thus reducing the spinal reflex. Dexmedetomidine showed a longer linear
dose-response relationship than clonidine, which was less effective at higher concentra-
tions. The difference was suggested to be due to the partial agonism of clonidine at the
α2-adrenoceptor or α1-adrenoceptor-mediated antagonism at higher concentrations
(Kendig et al., 1991). Both dexmedetomidine and isoflurane have been shown to suppress
nociceptive neurotransmission in the rat spinal cord, without significant interaction
between these drugs (Savola et al., 1991b). 
Some peripheral antinociceptive effect of dexmedetomidine has been reported, and it
may be mediated predominantly by a α1-adrenoceptor (Idänpään-Heikkilä et al., 1994).
The peripheral analgesic action of dexmedetomidine was enhanced after nerve injury
(Poree et al., 1998). 
2.4.4.1 Analgesic effects of dexmedetomidine in humans
Postoperatively administered iv dexmedetomidine relieved visceral pain and reduced opi-
oid requirement but was attended by sedation and bradycardia (Aho et al., 1991b).
Unexpectedly, in one study, patients treated with preoperative im dexmedetomidine expe-
rienced more pain than those patients treated with placebo (Aantaa et al., 1991b). Iv
dexmedetomidine showed an analgesic effect on ischaemic pain comparable with that of
fentanyl, but pain threshold (measured by dental dolorimetry) remained unaffected (Jaakola
et al., 1991). Pain threshold to electric stimulation of the tooth pulp and to cutaneous heat
were not influenced by a low dose of iv racemic medetomidine, however the unpleasant-
ness of ischaemic pain was reduced (Kauppila et al., 1991). While preoperative iv
dexmedetomidine decreased opioid requirements during hand surgery under regional
anaesthesia, it had no impact on pain sensation during tourniquet inflation (Jaakola, 1994).
Infusion of dexmedetomidine into volunteers decreased pain sensation and blood pressure
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response to the cold pressor test (Ebert et al., 2000; Hall et al., 2000) and prevented nora-
drenaline increase, without influencing adrenaline response (Ebert et al., 2000).
Intraoperative dexmedetomidine infusion (0.4-0.7 µg/kg/h) resulted in lower postoperative
pain scores and lower opioid requirements than propofol infusion (Arain & Ebert, 2002).
2.4.4.2 Analgesic effects of dexmedetomidine in animals
The analgesic effect of iv dexmedetomidine in dogs has been studied by a thermally evoked
skin twitch response and by toe-web pinching (Sabbe et al., 1994), and in anaesthetized
dogs by a tail-clamp method (Vickery et al., 1988; Bloor et al., 1992b; Nguyen et al., 1992;
Salmenperä et al., 1994). The effect of medetomidine, in contrast has been examined by
toe-web pinching (Clarke & England, 1989; England & Clarke, 1989; Hamlin & Bednarski,
1989; Venugopalan et al., 1998; Vainio, 1991), constant current stimulus (Vainio et al.,
1989) and skin needle-prick (Ko et al., 1996). Intrathecal, epidural and iv administration
of dexmedetomidine has been shown to produce an antinociceptive effect in dogs. After
intrathecal and epidural injection, a preferential reduction occurred in the response to
pinching of hind paws as compared with forepaws. The spinal effect was unaccompanied
by effects on behavioural alertness, motor function or changes in hypercapnic response
(Sabbe et al., 1994). Muir et al. (1999) observed no analgesic effect at im medetomidine
doses of 2 and 5 µg/kg in dogs of various breeds.  In beagles, im medetomidine 10 µg/kg
alleviated post-thoracotomy pain better than buprenorphine (Vainio & Ojala, 1994). In
canine ovariohysterectomy, im medetomidine 40 µg/kg administered preoperatively pro-
vided postoperative analgesia for up to 90 minutes after extubation (Ko et al., 2000).
In rats, the analgesic effect of dexmedetomidine has usually been measured by a spinal
reflex causing withdrawal of the paw or tail. Thermal nociception has been studied by a
hot-plate test (lick of the paw or a jump) (Idänpään-Heikkilä et al., 1994), a tail-flick test
(Kalso et al., 1991; Hayashi et al., 1995a; Guo et al., 1996) and a thermoelectric Peltier
device (Poree et al., 1998). Mechanical nociception has been evaluated by a paw pressure
test (Idänpään-Heikkilä et al., 1994) and von Frey fibres (Poree et al., 1998). According to
De Kock & Meert (1997), stress-induced analgesia may influence the antinociceptive action
of dexmedetomidine in rats, and thus housing and handling conditions of animals during
testing may affect the study outcome. Intrathecal administration of dexmedetomidine was
7 to 10 times more potent than sc administration in rats, and the antinociceptive effect
(six hours) outlasted the sedative effect (Kalso et al., 1991).
In cats, toe-web-, skin-, tail-pinching (Ansah et al., 1998; Ansah et al., 2000) and tail-
clamp (Farber et al., 1997; Schmeling et al., 1999) methods have been used to measure
the analgesic effect of dexmedetomidine. In cats, raising the blood concentration of
dexmedetomidine or medetomidine above a certain level decreased the level of sedation
while increasing the level of analgesia (Ansah et al., 2000).
2.4.5 Dexmedetomidine as a premedicant
While usefulness of dexmedetomidine as an anaesthetic adjunct has been extensively stud-
ied in humans, regulatory authorities have not yet approved it as a premedicant for
humans. Improved cardiovascular stability and the decrease in noradrenaline levels and
anaesthetic requirements are considered the most important beneficial effects of
dexmedetomidine during anaesthesia. The sympatholytic effect (bradycardia and hypoten-
sion) may be excessive in humans (Scheinin H et al., 1993; Talke et al., 1995; Lawrence &
DeLange, 1997). Perioperative oxygen consumption has been shown to effectively decrease
Kuusela  2.2.2004  15:10  Sivu 20
21
after dexmedetomidine (Taittonen et al, 1997). Its effect on perioperative myocardial
ischaemia prevention has been evaluated in vascular surgery patients, but patient numbers
have been too low to show statistical significance (Talke et al., 1995; Jalonen et al., 1997).
While haemodynamic responses to stressful stimuli are blunted by dexmedetomidine, it
may reduce the sensitivity of these variables as signs of anaesthetic depth (Erkola et al.,
1994).  
Dexmedetomidine reduces thiopental distribution and clearance, most probably by
decreasing cardiac output with no pharmacodynamic interaction between thiopental and
dexmedetomidine (Bührer et al., 1994). This is in contrast with the MAC-reducing effect
of dexmedetomidine with volatile agents (a pharmacodynamic interaction) (Vickery et al.,
1988; Aho et al., 1991a).
Dexmedetomidine reduces cerebral blood flow without evidence of global cerebral
ischaemia (Zornow et al., 1990). It is considered to be a potent neuroprotector (Maier et
al., 1993) and has been shown to prevent neonatal ischaemic brain damage in mice
(Laudenbach et al., 2002). It also reduces intra-ocular pressure in human cataract surgery
patients (Jaakola et al., 1992; Virkkilä et al., 1994).
2.4.5.1 Dexmedetomidine as a premedicant in humans
The optimal iv premedication dose of dexmedetomidine in humans has been reported to
be in the range of 0.33-0.67 µg/kg (Aantaa et al., 1990a), but higher (2 µg/kg) doses have
also been used (Lawrence & DeLange, 1997). The usual im dexmedetomidine premedica-
tion dose has been 2.5 µg/kg (Scheinin H et al, 1993; Levänen et al., 1995; Erkola et al.,
1994; Jaakola et al., 1994; Taittonen et al., 1997). Dexmedetomidine premedication has
been shown to reduce thiopental (Aantaa et al., 1990a; Aantaa et al., 1990b; Jaakola et
al., 1992; Scheinin B et al., 1992), isoflurane (Aho et al., 1991a; Jaakola et al., 1992; Erkola
et al., 1994; Lawrence & DeLange, 1997) and opioid (Aho et al., 1991b; Jaakola et al.,
1992; Scheinin B et al., 1992; Scheinin H et al., 1992, 1993; Jaakola et al., 1994; Lawrence
& DeLange, 1997) requirements. Dexmedetomidine decreased the need for intraoperative
ketamine and postanaesthetic delirium effects of ketamine, when compared with mida-
zolam (Levänen et al., 1995). Reduced cardiovascular responses to tracheal intubation (Aho
et al., 1991a; Aho et al., 1992b; Scheinin B et al., 1992; Scheinin H et al., 1993; Lawrence
& DeLange, 1997) and lower catecholamine concentrations (Scheinin B et al., 1992;
Scheinin H et al., 1992; Lawrence & DeLange, 1997) have been reported after dexmedeto-
midine. Recovery after isoflurane anaesthesia has been faster (Jaakola et al., 1992) or sim-
ilar (Lawrence & DeLange, 1997) when iv dexmedetomidine was compared with placebo
and similar when compared with midazolam-fentanyl (Jaakola et al., 1994). The haemo-
dynamic and sedative effects lasted at least four hours after im injection of the drug, which
was considered longer than optimal in connection with minor surgery (Aantaa et al.,
1991b). 
Intraoperative infusion of dexmedetomidine with a target plasma concentration of 0.6
ng/ml to 0.75 ng/ml has been shown to reduce isoflurane requirement by 47% to 90%
(Aho et al., 1992a; Aantaa et al., 1997; Khan et al., 1999a). In vascular surgery patients,
it decreased sympathetic tone and attenuated hyperdynamic responses to anaesthesia and
surgery but increased the propensity towards hypotension. The requirements of fentanyl,
enflurane and beta-blockers and the incidence of fentanyl-induced muscle rigidity and
postoperative shivering were decreased in patients receiving intraoperative dexmedetomi-
dine infusion (Jalonen et al., 1997).
Perioperative infusion of dexmedetomidine appeared to benefit haemodynamic man-
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agement of vascular surgical patients with less frequent episodes of tachycardia and
myocardial ischaemia in the dexmedetomidine group (Talke et al., 1995), and stress
responses during emergence of anaesthesia were attenuated (Talke et al., 2000). Sedation
was no longer observable the day after surgery despite the infusion of dexmedetomidine
continuing, probably due to the desensitizing effects of chronic administration of
dexmedetomidine (Talke et al., 1995). 
2.4.5.2 Dexmedetomidine as a premedicant in animals
In dogs, iv dexmedetomidine 10 µg/kg decreased the MAC of halothane by more than
90%. There was no response to tail-clamping for more than 1 hour despite halothane was
discontinued (Vickery et al., 1988; Vickery & Maze, 1989). Iv dexmedetomidine 20 µg/kg
decreased the MAC of isoflurane by 89%. The isoflurane requirement was still 50%
reduced at four hours after administration of dexmedetomidine (Bloor et al., 1992b). A
low dose of 3 µg/kg of iv dexmedetomidine reduced isoflurane MAC by 70% (Nguyen et
al., 1992). In dogs under enflurane anaesthesia, iv dexmedetomidine and fentanyl showed
an additive or synergistic interaction with respect to MAC-sparing effect, but the presence
of fentanyl increased the degree of bradycardia induced by dexmedetomidine (Salmenperä
et al., 1994). Oral dexmedetomidine premedication has also been studied in dogs (Proctor
et al., 1991, 1992; Kersten et al., 1993). 
Räihä et al. (1989) suggested that the most suitable im premedicant dose of racemic
medetomidine in dogs is between 10 and 40 µg/kg, as the lower dose produced incon-
sistent sedation, and the higher dose excessive sedation. In a clinical study in dogs of var-
ious breeds, an im dose of 20 µg/kg of medetomidine (corresponding to 10 µg/kg of
dexmedetomidine) was suggested to be optimal for premedication (Young et al., 1990).
In rats, halothane could be discontinued for up to 30 min with no response to tail-
clamping after ip dexmedetomidine 100 µg/kg (Segal et al., 1988), and the same dose
reduced isoflurane MAC by approximately 90% (Savola et al., 1991a). Schmeling et al.
(1999) found that in cats receiving dexmedetomidine lower brainstem or spinal determi-
nants of anaesthetic depth (movement and haemodynamic responses) were more attenu-
ated than those of higher brain functions, such as those detected in an electroencephalo-
gram. In miniature swine anaesthetized with dexmedetomidine and isoflurane, hypother-
mia profoundly affected anaesthetic requirement and duration of action of dexmedeto-
midine (Vainio & Bloor, 1994).
2.4.6 Effects of dexmedetomidine on stress hormones
Dexmedetomidine requires only a slight α2-adrenoceptor availability to decrease nora-
drenaline turnover (Rabin et al., 1996b), and very low doses of dexmedetomidine result in
sympatholysis (Flacke et al., 1993). Thus, patients in need of a high level of sympathetic
tone to maintain blood pressure may not tolerate even low doses of dexmedetomidine
(Bloor et al., 1992a). However, in postoperative patients, sympathetic tone was not entire-
ly abolished by dexmedetomidine infusion, and merely the unwanted increases in heart
rate and blood pressure were attenuated (Talke et al., 1997). Very high doses of
dexmedetomidine have been shown to inhibit steroidogenesis in dogs, the peak effect fol-
lowing the peak hypnotic action, but a biologically important influence on steroidogene-
sis is considered unlikely (Maze et al., 1991). Dexmedetomidine infusion did not inhibit
adrenal steroidogenesis in humans after major surgery (Venn et al., 2001). 
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2.4.6.1 Effects of dexmedetomidine on stress hormones in humans
Dexmedetomidine dose-dependently decreased plasma noradrenaline levels up to 90%
(Kallio et al., 1989; Aantaa et al., 1990a; b, 1991b; Bloor et al., 1992b; Scheinin H et al.,
1992; Jaakola et al., 1994; Lawrence & DeLange, 1997; Ebert et al., 2000), and plasma
adrenaline levels were usually decreased as well (Bloor et al., 1992a; Scheinin H et al.,
1992; Lawrence & DeLange, 1997; Ebert et al., 2000). The effect of dexmedetomidine on
cortisol and beta-endorphin levels has received less attention. Cortisol levels have been
shown to be unaffected by dexmedetomidine (Kallio et a.l, 1989; Aantaa et al., 1990b) or
increased less after dexmedetomidine than after placebo in response to surgery (Aho et
al., 1992b). Plasma levels of beta-endorphin followed a similar pattern (Aho et al., 1992b).  
2.4.6.2 Effects of dexmedetomidine on stress hormones in dogs
Iv dexmedetomidine has been shown to decrease catecholamine levels in dogs (Schmeling
et al., 1991; Bloor et al., 1992b; Flacke et al., 1993; Roekaerts et al., 1996, 1997; Willigers
et al., 2003). Very high dexmedetomidine doses have been reported to release cate-
cholamines from cardiac stores in dogs (Flacke et al., 1992). In dogs undergoing thoracic
surgery (induced myocardial ischaemia), infusion of dexmedetomidine 0.6 µg/kg/h had no
effect on plasma cortisol levels (Willigers et al., 2003). 
Clinical doses of im racemic medetomidine had no influence on canine cortisol levels
(Ambrisko & Hikasa, 2002) but delayed the cortisol response induced by ovariohysterec-
tomy (Benson et al., 2000; Ko et al., 2000). After thoracotomy, catecholamine levels were
lower in dogs receiving im medetomidine than in those receiving buprenorphine (Vainio &
Ojala, 1994). In dogs undergoing ovariohysterectomy, catecholamine and cortisol levels
were lower after im medetomidine than after acepromazine premedication; however, the
concentration of beta-endorphin did not differ between the premedicant groups (Väisänen
et al., 2002). 
2.4.7 Adverse effects caused by dexmedetomidine
In humans, dexmedetomidine has generally been well tolerated (Kallio et al., 1989; Aantaa
et al., 1990a, 1990b; Jaakola et al., 1991; Bloor et al., 1992b; Aho et al., 1992b; Scheinin
H et al., 1992; Jaakola, 1995). Fatigue, decreased salivation (Kallio et al., 1989; Aantaa et
al., 1990a, 1990b), nausea (Venn et al., 1999), discomfort and agitation (Dutta et al.,
2000; Ebert et al., 2000) have been described in single cases after dexmedetomidine.
In dogs, hypothermia, muscular twitching and vomiting are the most commonly
described adverse effects after medetomidine administration (Vainio, 1989; England &
Clarke, 1989; Hamlin & Bednarski, 1989). 
2.5 Levomedetomidine
Levomedetomidine is considered to be pharmacologically inactive (MacDonald et al., 1991,
Savola & Virtanen, 1991, Aantaa et al., 1993). However, it has been shown to be involved
in kinetic drug interactions by prolonging the hepatic metabolism of hexobarbital (Pelkonen
et al., 1991), alfentanil (Kharasch et al., 1991) and ketamine (Kharasch et al., 1992). In a
radioligand assay, levomedetomidine bound similarly to all α2-adrenoceptor subtypes but
with a lower affinity than dexmedetomidine (Jansson et al., 1994). Levomedetomidine is
also capable of binding to and activating α1-adrenoceptors, albeit more weakly than
dexmedetomidine (Schwinn et al., 1991). The α2- to α1-adrenoceptor selectivity ratio
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reported for dexmedetomidine is 1300, whereas that of levomedetomidine is 23 (Aantaa
et al., 1993). Levomedetomidine has been shown to have affinity towards cerebral imida-
zoline-receptors as well but again, less than dexmedetomidine (Wikberg et al., 1991).
Levomedetomidine was as efficacious as dexmedetomidine in blocking adrenocorti-
cotrophic hormone (ACTH) -stimulated corticosterone production in vitro, suggesting that
the imidazole structure and not the anaesthetic potency led to inhibition of steroidogen-
esis (Maze et al., 1991).
In vitro studies have demonstrated that levomedetomidine may act as a weak partial
α2-adrenoceptor agonist (Jansson et al., 1994) or as an inverse α2-adrenoceptor agonist
(negative antagonist), depending on the test system and the constitutive activity of the
receptors (Jansson et al., 1998). It inhibited the contraction of the rat vas deferens, the
maximum response being 30% of that to dexmedetomidine (Jansson et al., 1998).  The
enantiomers showed opposite effects on signal transduction through the α2A-adrenocep-
tor. Dexmedetomidine acted as an agonist by elevating Ca2+ and inhibiting cAMP pro-
duction, and levomedetomidine acted as an inverse agonist by reducing Ca2+ and enhanc-
ing cAMP production. Both effects were abolished by pertussis toxin, suggesting trans-
duction through pertussis toxin- sensitive G-proteins (Jansson et al., 1998).  
In vivo studies of the effects of levomedetomidine are scarce. Cardiorespiratory
changes associated with levomedetomidine have not been reported, and the behavioural
alterations that have been published are difficult to interpret. Levomedetomidine (99.7%
optical purity) has been claimed to have some sedative and analgesic properties at very
high doses in rats (Savola & Virtanen, 1991). It was shown to prolong sleeping time in rats
sedated with hexobarbital (Pelkonen et al., 1991; Savola & Virtanen, 1991), probably due
to kinetic interaction (Pelkonen et al., 1991). In rats, ip levomedetomidine 10, 30 and 100
µg/kg had no effect on the MAC of halothane (Segal et al., 1988) and it was without hyp-
notic effects even at a dose of 30 mg/kg ip (Doze et al, 1989a), however, a dose of 10
mg/kg sc provoked arousal (MacDonald et al., 1991). In mice, ip levomedetomidine (100
and 300 µg/kg) increased cGMP content, while dexmedetomidine decreased it at doses
that typically cause sedation (Vulliemoz et al., 1996). In tadpoles, levomedetomidine
showed some anaesthetic effects and adhered to the Meyer-Overton correlation (Tonner
et al., 1997).
Schmeling et al. (1991) demonstrated that low (< 5 µg/kg iv) doses of levomedetomi-
dine did not alter the haemodynamics, arterial blood gas tensions or noradrenaline plas-
ma concentrations in conscious dogs. Administration of 1, 3 or 10 µg/kg of levomedeto-
midine iv had no effect on the haemodynamics or MAC in halothane-anaesthetized dogs
(Vickery et al., 1988). Levomedetomidine 0.2 or 0.5 µg/kg/min did not affect the arrhyth-
mogenic dose of adrenaline in dogs under halothane anaesthesia, while dexmedetomidine
increased the arrhythmogenic threshold (Hayashi et al., 1991). In rats, iv levomedetomi-
dine (0.1 to 10 mg/kg, 99.7% optical purity) did not change blood pressure or heart rate
(Savola & Virtanen, 1991), and doses of 1 µg administered intracranially or 50 µg/kg
administered iv had no effect on the rostral ventrolateral medulla activity or blood pres-
sure (Hong et al., 1992). Medetomidine and dexmedetomidine induced a mydriatic
response in rats, but levomedetomidine was inactive (Savola & Virtanen, 1991).
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2.6 Medetomidine-dexmedetomidine comparisons in
different species
In rats, the following half-maximal effects were obtained after iv medetomidine and
dexmedetomidine: decreased heart rate (at doses of 0.4 and 0.5 µg/kg for medetomidine
and dexmedetomidine, respectively), decreased arterial pressure (1.0 and 0.6 µg/kg),
reduced motility (35 and 20 µg/kg), prolonged hexobarbital sleeping time (30 and 20
µg/kg), analgesic properties (20 and 10 µg/kg) and mydriatic response (4 and 2 µg/kg)
(Savola & Virtanen, 1991). In cats, while the duration of sedation was shorter after im
dexmedetomidine 50 µg/kg than after medetomidine 100 µg/kg, it was longer after
dexmedetomidine 75 µg/kg than after medetomidine 150 µg/kg (Ansah et al., 1998).
When dexmedetomidine and medetomidine were administered to cats as an infusion at
three dose levels, no significant differences were observed between the drugs for seda-
tion, analgesia, muscular relaxation and heart and respiratory rates (Ansah et al., 2000). In
sheep undergoing orthopaedic surgery, premedication with iv dexmedetomidine 5 µg/kg
or medetomidine 10 µg/kg had the same effects on isoflurane requirements and car-
diopulmonary parameters (Kästner et al., 2001a). Im dexmedetomidine 15 µg/kg or
medetomidine 30 µg/kg resulted in similar isoflurane requirements in sheep, but heart rate
was higher and the partial pressure of oxygen less variable in the dexmedetomidine group
(Kästner et al., 2001b). 
2.7 Current knowledge of dexmedetomidine and
levomedetomidine in dogs
Published studies of dexmedetomidine and levomedetomidine in dogs are presented in
Table 1. The doses of dexmedetomidine vary between 0.1 and100 µg/kg, and those of
levomedetomidine between 1 and 10 µg/kg. The route of administration has usually been
iv, and most of the studies have been conducted while dogs were anaesthetized. The
effects of dexmedetomidine and medetomidine have not been compared in conscious
dogs. No studies exist in which dexmedetomidine has been used as a sedative and pre-
medicant in dogs clinically, similar to medetomidine. Moreover the sedative, analgesic and
cardiovascular effects of dexmedetomidine and levomedetomidine in conscious dogs
remain unknown. While the pharmacokinetics of medetomidine in dogs has been report-
ed (Salonen 1989), the pharmacokinetics of dexmedetomidine and levomedetomidine in
dogs is yet to be determined. The recovery profile after dexmedetomidine premedication
and the pharmacological effect of levomedetomidine in dogs also remain obscure. The
effects of dexmedetomidine and levomedetomidine on the adrenaline arrhythmic thresh-
old during halothane anaesthesia have been revealed, but no other reports are available
on ECG findings after administration of these drugs. 
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Table 1
Published studies of dexmedetomidine in dogs
• Doses, administration routes and other drugs
1. Vickery et al., 1988 (1, 3 and 10 µg/kg iv/20 min, cumulative, under halothane)
2. Flacke et al., 1990 (1-30 µg/kg iv bolus or over 20 min, cumulative, under isoflurane)
3. Zornow et al., 1990 (10 µg/kg iv/10 min, under isoflurane)
4. Schmeling et al., 1991 (1.25, 2.5 and 5 µg/kg iv/10min, cumulative, conscious)
5. Maze et al., 1991 (80 µg/kg im/sc, conscious) 
6. Proctor et al., 1991 (10 and 20 µg/kg per os, conscious and before enflurane)
7. Hayashi et al., 1991 (0, 0.1, 0.2 and 0.5 µg/kg/min infusion, under halothane)
8. Karlsson et al., 1990 (10 µg/kg iv/15 min, under halothane) 
9. Bloor et al., 1992 (20 µg/kg iv/2 min, under isoflurane) 
10. Nguyen et al., 1992 (1,10, 20 and 100 µg/kg iv, conscious and 3 µg/kg iv under isoflurane) 
11. Gregoretti et al., 1992 (3 and 30 µg/kg iv, under halothane )
12. Proctor et al., 1992 (20 µg/kg per os, conscious and before propofol, ketamine and etomidate)
13. Flacke et al., 1993 (0.25, 0.5, 1.0, 2.0 and 4.0 µg/kg iv, cumulative, under isoflurane) 
14. Kersten et al., 1993 (30 µg/kg per os, conscious and before isoflurane and desflurane)
15. Sabbe et al., 1994 (1, 3 and 10 µg/kg iv (+ intrathecal, epidural, intracisternal))
16. Salmenperä et al., 1994 (0.1-10 µg/kg iv cumulative, under enflurane and enflurane and 
fentanyl)
17. Kamibayashi et al., 1995a (0, 0.2, 0.5 µg/kg/min infusion, under halothane)
18. Kamibayashi et al., 1995b (0.5 µg/kg/min infusion, under halothane)
19. Ishiyama et al., 1995 (topical application to pial vessels)
20. Lawrence et al., 1996a (0.1, 1 and 10 µg/kg iv/2 min, cumulative, under fentanyl/halothane
and chloralose/urethane)
21. Lawrence et al., 1996b (0.1, 0.3, 1, 3 and 10 µg/kg iv/2 min, cumulative, 
under fentanyl/halothane and chloralose/urethane) 
22. Roekaerts et al., 1996 (1 and 3 µg/kg iv, under halothane)
23. Roekaerts et al., 1997 (0.1, 0.3, 1.0, 3.0 and 10 µg/kg iv/1 min, cumulative, under fentanyl) 
24. Pagel et al., 1998a (1, 2.5, 5 µg iv cumulative, conscious) 
25. Pagel et al., 1998b (5 µg/kg iv, conscious)
26. Kaivosaari et al., 2002 (liver microsomes)
27. Willigers et al., 2003 (0.6 µg/kg/h infusion, under halothane)
• Sedative effects 15
• Analgesic effects 15
• Anaesthetic-sparing effects 1, 9, 10, 16
• Cardiovascular effects, anaesthetized dogs 1, 2, 3, 6, 8, 9, 11, 12, 13, 14, 16, 20, 21, 
22, 23, 27   
• Cardiovascular effects, conscious dogs 4, 6, 12, 14, 24, 25
• Respiratory effects, anaesthetized dogs, controlled ventilation 1, 6
• Respiratory effects, anaesthetized dogs, spontaneous ventilation 10
• Respiratory effects, conscious dogs 4, 6, 10, 15
• Pharmacokinetics 15 (in cerebrospinal fluid), 26 (glucuronidation)
• Recovery 6, 27
• Arrhythmias (adrenaline threshold) 7, 17, 18
• Stress hormones, anaesthetized dogs 2, 6, 9, 13, 14, 22, 23, 27   
• Stress hormones, conscious dogs 4, 5, 6, 14
Published studies of levomedetomidine in dogs
• Doses, administration routes and other drugs  
1. Vickery et al., 1988 (1, 3 and 10 µg/kg iv/20 min, cumulative, under halothane)
4. Schmeling et al., 1991 (1.25, 2.5 and 5 µg/kg iv/10 min, cumulative, conscious) 
7. Hayashi et al., 1991 (0.2 and 0.5 µg/kg/min infusion, under halothane)
• Cardiovascular effects 1, 4
• Respiratory effects 1, 4
• Arrhythmias  (adrenaline threshold) 7
• Stress hormones 4
• Dexmedetomidine-levomedetomidine comparisons 1, 4
• Dexmedetomidine-medetomidine comparisons 1
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3. AIMS OF THE STUDY
1) To investigate the clinical effects and pharmacokinetics of medetomidine, dexmedeto-
midine and levomedetomidine in dogs to determine whether dexmedetomidine offers
any benefit over racemic medetomidine (I, II, III).
2) To determine whether levomedetomidine has any pharmacological activity or whether
it influences the sedative and analgesic effects of dexmedetomidine in dogs (II).
3) To determine the most appropriate premedicant dose level of dexmedetomidine in dogs
(III).
4) To compare clinical responses to propofol infusion and propofol/isoflurane anaesthesia
in dexmedetomidine premedicated dogs, both during anaesthesia and the recovery peri-
od (IV). 
5) To evaluate the suitability of a cold pressor test (CPT) as a stress stimulus using dogs
sedated and premedicated with dexmedetomidine as a model (IV).
6) To assess the effects of dexmedetomidine premedication and propofol/isoflurane or
propofol infusion anaesthesia on the incidence of arrhythmias in healthy dogs during
the perianaesthetic period (V). 
Kuusela  2.2.2004  15:10  Sivu 27
28
4. MATERIALS AND METHODS
4.1 Animals
The same six healthy beagles, three females (dogs 1, 2 and 3) and three males (dogs 4, 5
and 6), were used. The dogs were aged from 10 months to 3 years during the studies. The
males were castrated before Study II and females were ovariohysterectomized before
Studies IV and V. The dogs were not used for any other purposes. They were group-housed
and received outdoor exercise daily. They were regularly vaccinated and dewormed. Dogs
2 and 3 were littermates, as were dogs 4 and 6. Before starting the experiments, the dogs
were trained to handling and adapted to the study rooms. 
4.2 Drugs and dosages
The effects of medetomidine (Domitor, Orion Pharma, Turku, Finland), dexmedetomidine
(Orion Pharma) and levomedetomidine (Orion Pharma) were studied. All drugs were in the
form of hydrochlorides. The study designs are summarized in Table 2. 
Study I: Each dog was studied six times on separate days. Medetomidine 40 µg/kg,
dexmedetomidine 20 µg/kg, dexmedetomidine 10 µg/kg, levomedetomidine 20 µg/kg, lev-
omedetomidine 10 µg/kg and saline placebo were administered as an iv bolus.
Study II: Each dog was studied three times on separate days. The dogs were adminis-
tered a low dose of levomedetomidine (10 µg/kg) as an iv bolus, followed by infusion at
a dose of 25 µg/kg/h; a high dose of levomedetomidine (80 µg/kg), followed by infusion
at a dose of 200 µg/kg/h; and saline, followed by saline infusion. The infusions were con-
tinued for 120 minutes, and at 60 minutes, 10 µg/kg of dexmedetomidine was adminis-
tered as an iv bolus.
Study III: Each dog was studied six times on separate days. Medetomidine 0.4 µg/kg,
4 µg/kg and 40 µg/kg and dexmedetomidine 0.2 µg/kg, 2 µg/kg and 20 µg/kg were
administered as an iv bolus as premedication preceding a light level of propofol/isoflurane
anaesthesia.
Studies IV and V: Each dog was studied six times on separate days. Dexmedetomidine
10 µg/kg was administered im as premedication before propofol/isoflurane (end tidal
1.0%; twice) or propofol infusion (200 µg/kg/min; twice) anaesthesia or premedication
alone (twice).
4.3 Clinical signs of sedation, analgesia and 
anaesthesia
The effects were evaluated subjectively by the main investigator (E.K). The scoring of seda-
tive and analgesic effects in Study III in presented in Table 3. The scoring systems were not
exactly the same in Studies I, II and III. The sedative effects were assessed by observing
spontaneous posture, palpebral reflex, position of eye, relaxation of jaws and tongue,
response to sound (I, II), resistance when laid laterally recumbent and general appearance
(Clarke & England, 1989; Vainio et al., 1989). The analgesic effect was assessed by pinch-
ing the interdigital skin of a hind foot to observe withdrawal reflex (Clarke & Enland, 1989;
Sabbe et al., 1994; Quandt et al., 1998). 
The depth of anaesthesia was determined by observing the ocular reflexes and eye
position, relaxation of jaws and tongue, and motoric, haemodynamic and respiratory
Kuusela  2.2.2004  15:10  Sivu 28
29
Ta
b
le
 2
. S
u
m
m
ar
y 
o
f 
th
e 
st
u
d
y 
d
es
ig
n
s.
St
ud
y
N
um
be
r 
of
 
D
es
ig
n
C
on
tr
ol
 d
ru
g
D
ru
gs
, 
do
se
s 
an
d 
ro
ut
es
  
M
on
ito
rin
g
do
gs
of
 a
dm
in
is
tr
at
io
n
I
6
Ra
nd
om
iz
ed
 6
x6
 
Sa
lin
e
M
ed
 4
0 
µg
/k
g 
iv
Se
da
tio
n,
 a
na
lg
es
ia
, 
ca
rd
io
re
sp
ira
to
ry
 
La
tin
 s
qu
ar
e
D
ex
 1
0 
an
d 
20
 µ
g/
kg
 iv
pa
ra
m
et
er
s,
 D
ex
 a
nd
 L
ev
o 
pl
as
m
a
Bl
in
de
d
Le
vo
 1
0 
an
d 
20
 µ
g/
kg
 iv
co
nc
en
tr
at
io
ns
, 
no
ra
dr
en
al
in
e,
Pl
ac
eb
o-
co
nt
ro
lle
d
ad
re
na
lin
e
II
6
Ra
nd
om
iz
ed
  
6x
3 
Sa
lin
e
Le
vo
 1
0 
µg
/k
g 
iv
 +
 2
5 
µg
/k
g/
h 
+
Se
da
tio
n,
 a
na
lg
es
ia
, 
ca
rd
io
re
sp
ira
to
ry
 
cr
os
s-
ov
er
D
ex
 1
0µ
g/
kg
 iv
pa
ra
m
et
er
s,
 D
ex
 a
nd
 L
ev
o 
pl
as
m
a
Bl
in
de
d
Le
vo
 8
0 
µg
/k
g 
iv
 +
 2
00
 µ
g/
kg
/h
  
co
nc
en
tr
at
io
ns
, 
no
ra
dr
en
al
in
e,
Pl
ac
eb
o-
co
nt
ro
lle
d
+
 D
ex
 1
0 
µg
/k
g 
iv
ad
re
na
lin
e
III
6
Ra
nd
om
iz
ed
 6
x6
M
ed
 0
.4
, 
4.
0 
an
d 
40
 µ
g/
kg
 iv
 *
*
Se
da
tio
n,
 a
na
lg
es
ia
, 
ca
rd
io
re
sp
ira
to
ry
La
tin
 s
qu
ar
e
D
ex
 0
.2
, 
2.
0 
an
d 
20
 µ
g/
kg
 iv
 *
*
pa
ra
m
et
er
s,
 p
ro
po
fo
l d
os
e,
 e
nd
-t
id
al
Bl
in
de
d 
fo
r 
th
e 
dr
ug
is
of
lu
ra
ne
 c
on
ce
nt
ra
tio
n,
 r
ec
ov
er
y
IV
6
Ra
nd
om
iz
ed
 6
x6
 
D
ex
 1
0 
µg
/k
g 
im
 *
**
D
ep
th
 o
f 
an
ae
st
he
si
a,
 c
ar
di
or
es
pi
ra
to
ry
La
tin
 s
qu
ar
e
pa
ra
m
et
er
s,
 n
or
ad
re
na
lin
e,
 a
dr
en
al
in
e,
be
ta
-e
nd
or
ph
in
, 
co
rt
is
ol
, 
re
co
ve
ry
,
co
ld
 p
re
ss
or
 t
es
t
V
 *
6
Ra
nd
om
iz
ed
 6
x6
 
D
ex
 1
0 
µg
/k
g 
im
**
*
H
ol
te
r
La
tin
 s
qu
ar
e
M
ed
 =
 m
ed
et
om
id
in
e,
 D
ex
 =
 d
ex
m
ed
et
om
id
in
e,
 L
ev
o 
=
 le
vo
m
ed
et
om
id
in
e
* 
M
at
er
ia
l f
or
 S
tu
dy
 V
 w
as
 c
ol
le
ct
ed
 d
ur
in
g 
St
ud
y 
IV
**
 P
ro
po
fo
l/i
so
flu
ra
ne
 a
na
es
th
es
ia
**
* 
Pr
op
of
ol
/is
of
lu
ra
ne
 o
r 
pr
op
of
ol
 in
fu
si
on
 a
na
es
th
es
ia
Kuusela  2.2.2004  15:10  Sivu 29
30
responses to noxious stimulus (interdigital pinching in Study III). In Study III, the dogs were
kept in a light plane of anaesthesia, which was characterized by lack of purposeful move-
ment in response to interdigital pinching for 3 seconds, moderate relaxation of the jaws,
eye rotation, and presence of a palpebral reflex. Noxious stimulus was applied every 5 min-
utes. If there was no haemodynamic or respiratory response to pinching, concentration of
isoflurane was slightly decreased. If the dog flexed its leg or moved its head or tongue,
concentration of isoflurane was slightly increased.
4.4 Cold pressor test
In Study IV, the suitability of a cold pressor test (CPT) (Short & Paddleford, 1996; Short,
1999; Ebert et al., 2000; Hall et al., 2000) as a noxious stimulus was evaluated. Dogs were
premedicated with im dexmedetomidine 10 µg/kg and tested every 15 minutes during
Table 3.
Scoring of sedation in Study III
1. Position 
0 Standing, 1 Standing but staggers, 2 Sternal head up, 3 Sternal head down, 
4 Lateral head down
2. Palpebral reflex 
0 Normal, 1 Slightly reduced, 2 Weak, 3 Absent
3. Position of the eye 
0 Middle, 2 Turned down
4. Jaw and tongue relaxation
0 Normal, opens the jaws but resists manipulation of the tongue, 1 Bites jaws 
together, 2 Opens the jaws but strong resistance when tongue is pulled,
3 Slight resistance when tongue is pulled, 4 No resistance when tongue is pulled
5. Resistance to positioning in lateral recumbency 
0 Normal, 1 Turns back to sternal position, 2 Some resistance but stays in lateral 
position, 3 No resistance or the position is already lateral
6. General appearance
0 Normal, 1 Slightly tired, head drooping, 2 Mild sedation, reacts clearly to 
surroundings, 3 Moderate sedation, reacts mildly to surroundings, 4 Deep 
sedation, no reaction to surroundings 
Scoring of analgesia in Study III
0 Normal pedal reflex, immediate withdrawal, 1 Slow reflex, 2 Withdrawal of foot
only after pinching with increased intensity for 3 seconds, 3 No response
The effect was tested by pinching the interdigital skin of an extended hind foot. 
To avoid unnecessary pain, pinching was initiated lightly with fingernails and
stopped immediately when a pedal reflex was induced.
Kuusela  2.2.2004  15:10  Sivu 30
31
dexmedetomidine sedation, propofol/isoflurane anaesthesia and propofol infusion anaes-
thesia, starting before induction. CPT was performed by dipping the front leg to the level
of the carpal joint in 0˚C ice water for one minute or until the dog lifted the paw. The dog
was not moved during testing. Cardiorespiratory parameters and level of anaesthesia were
determined and blood samples were taken before the stimulus. The cardiorespiratory
parameters were rerecorded immediately after the stimulus, and the difference was used
to show the immediate effect of CPT. 
4.5 Cardiorespiratory effects
Heart rate and direct blood pressure were monitored via a catheter in a femoral artery.
Timed lead II electrocardiograms were recorded in Studies I and II. The recordings were
analysed mainly for heart rate and incidence of atrioventricular (AV) blocks and ventricu-
lar premature contractions (VPC). AV-blocks were defined as follows (Tilley 1992):
First-degree AV-block: the P-R interval is longer than 0.13 seconds.
Second-degree AV-block: one or more P waves are not followed by QRS-T complexes.
No attempt was made to classify these to Mobitz type I or II.
Sinus pause was defined as a pause greater than twice the normal R-R interval.
Continuous perianaesthetic 24-hour Holter recordings were made in Study V. The
electrodes were placed around the dog's chest, and the recorder was placed in the pock-
et of a jacket designed for this purpose. The amount of VPCs, second and third degree
AV-blocks, and mean heart rate/hour were counted and the longest sinus pauses were
reported. 
Respiratory rate was calculated by observing the movements of the dog's chest (I-IV)
or by using a monitor (III and IV). Arterial blood samples were taken from the catheter for
immediate blood gas analysis in Studies I-IV. In addition, plasma lactate concentration was
determined in Study IV. Arterial haemoglobin saturation was estimated in Study III by using
a pulse oximeter. 
4.6 Pharmacokinetic studies
Blood samples for plasma drug (medetomidine, dexmedetomidine, or levomedetomidine)
concentration determinations were collected in Studies I and II. The samples were obtained
from an arterial catheter, and plasma was separated, frozen and later analysed by capillary
gas chromatography with mass spectrometry detection. In Study I, total clearance, volume
of distribution at steady state and terminal half-life were calculated for each drug and
dosage.
4.7 Stress hormone studies
In Studies II and IV, plasma adrenaline and noradrenaline concentrations were determined,
as well as plasma beta-endorphin and cortisol concentrations in Study IV. All samples were
obtained via an arterial catheter. A catecholamine assay was done using high-performance
liquid chromatography. Beta-endorphin and cortisol concentrations were analysed by
radioimmunoassay. Baseline plasma beta-endorphin concentration in these beagles was
measured separately by obtaining jugular venous blood samples twice in each dog. 
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4.8 Statistical analyses
Numerical variables were analysed by use of repeated-measures analysis of variance (ANO-
VA), and categorical variables were analysed by use of the non-parametric Friedman test
(I-III) or Cochran-Mantel-Haenszel test (IV). Values of P<0.05 were considered significant.
Data are expressed as mean ± standard deviation (SD). Additionally, 95% confidence inter-
vals (CI) were calculated for some of the main results.
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5. RESULTS
5.1 Clinical signs of sedation, analgesia and
anaesthesia
5.1.1 Effects of medetomidine and dexmedetomidine on clinical
signs of sedation and analgesia (I, II, IV)
The overall level of sedation did not differ between iv medetomidine 40 µg/kg, dexmedeto-
midine 20 µg/kg and dexmedetomidine 10 µg/kg during the first hour (Figure 3). Sedation
caused by the higher dose of dexmedetomidine lasted longer than that of dexmedetomi-
dine 10 µg/kg. The dogs stayed laterally recumbent longer after dexmedetomidine 20
µg/kg than after medetomidine 40µg/kg or dexmedetomidine 10 µg/kg. All treatments
caused significant analgesia, but analgesia lasted longer after dexmedetomidine 20 µg/kg
than after medetomidine 40 µg/kg or dexmedetomidine 10 µg/kg (I). In Study III, the
effects of iv medetomidine and dexmedetomidine were similar with respect to sedation
and analgesia 10 minutes after administration. After receiving the higher doses (40 and
20 µg/kg for medetomidine and dexmedetomidine, respectively), the dogs were deeply
sedated and showed good analgesia. Doses 4 and 2 µg/kg caused moderate sedation and
light analgesia respectively. Doses 0.4 and 0.2 µg/kg caused very slight sedation and no
analgesia, respectively. In Study IV, the dogs were recumbent after im dexmedetomidine
10 µg/kg in a mean time of 11.9 ± 3.5 minutes. 
5.1.2 Cold pressor test (IV)
During im dexmedetomidine sedation one female dog responded to CPT every time and
two other females once by withdrawing the paw from ice water. Respiratory rate increased
before induction and 15 minutes after induction in response to CPT (IV).
5.1.3 Effects of levomedetomidine on clinical signs of sedation and
analgesia (I, II)
An iv bolus of levomedetomidine (10 or 20 µg/kg) or placebo did not cause any apparent
signs of sedation or analgesia. However, two dogs seemed somewhat tired although stand-
ing after administration of levomedetomidine 10 µg/kg, and one dog appeared slightly
nervous after levomedetomidine 20 µg/kg (I). In Study (II), levomedetomidine (10 or 80
µg/kg iv followed by continuous infusion at a dose of 25 µg/kg/h or 200 µg/kg/h, respec-
tively) or placebo caused no observable signs of sedation, analgesia or behavioural
changes. The overall degree of sedation was higher when dexmedetomidine was given
alone than when given in combination with either dose of levomedetomidine (Figure 4).
The analgesic effect was more profound with dexmedetomidine alone than with
dexmedetomidine combined with the higher dose of levomedetomidine.
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Figure 3
Estimated total sedation (TotSed) scores (A) and estimated difference with 95% CI between medeto-
midine 40 µg/kg (Med40) and dexmedetomidine 10 µg/kg (Dex10) (B); between medetomidine 40
µg/kg and dexmedetomidine 20 µg/kg (Dex20) (C); between dexmedetomidine 10 µg/kg and
dexmedetomidine 20 µg/kg (D) after iv dosing in six dogs. (Study I)
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Figure 4 
Estimated total sedation (TotSed) scores (A) and estimated difference with 95% CI between iv lev-
omedetomidine 25 µg/kg/h (Low Levo) and levomedetomidine 200 µg/kg/h (High Levo) (B); between
levomedetomidine 25 µg/kg/h and saline (Control) (C); between levomedetomidine 200 µg/kg/h and
saline (D) in six dogs. The dogs received dexmedetomidine 10 µg/kg iv at 60 minutes. (Study II)
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5.1.4 Effects of premedicants on anaesthesia and recovery profile
(III, IV)
The amount of propofol required for induction was similar for medetomidine and
dexmedetomidine but was affected by the dose level of premedicant. Combined mean
end-tidal isoflurane concentration was higher when dogs received iv medetomidine (0.4,
4 and 40 µg/kg), compared with iv dexmedetomidine (0.2, 2 and 20 µg/kg). The overall
interaction effect of drug x dose x time was not statistically significant. However, the 95%
confidence intervals for differences presented in Figure 5 indicates significantly lower isoflu-
rane concentrations for dexmedetomidine 2 µg/kg than for medetomidine 4 µg/kg at cer-
tain time-points. Recovery time was prolonged when dogs were treated with iv medeto-
midine 40 µg/kg and dexmedetomidine 20 µg/kg, as compared with the lower dose lev-
els, but the dogs were always extubated within 10 minutes after the end of anaesthesia
(III). 
Palpebral reflexes were more distinct when dogs received propofol infusion than dur-
ing propofol/isoflurane anaesthesia. Recovery times (extubation, head lift, standing) were
longer after propofol than after propofol/isoflurane anaesthesia; however, recovery times
(head lift, standing) after premedication only were similar to propofol/isoflurane (IV). In
both studies (III and IV) recoveries were smooth with no signs of nausea.
5.2 Cardiorespiratory effects
5.2.1 Cardiovascular effects of medetomidine and
dexmedetomidine (I-V)
In general, medetomidine and dexmedetomidine had similar effects on the cardiovascular
parameters (I, III; Figures 6 and 7). After administration of iv medetomidine 40 µg/kg,
dexmedetomidine 20 µg/kg and dexmedetomidine 10 µg/kg arterial blood pressures
increased transiently and heart rate decreased (I, II, III). During anaesthesia in Study III, heart
rate remained above baseline after premedication with iv medetomidine 0.4 µg/kg
/dexmedetomidine 0.2 µg/kg and below baseline with iv medetomidine 4 µg/kg
/dexmedetomidine 2 µg/kg or medetomidine 40 µg/kg /dexmedetomidine 20 µg/kg.
Overall heart rate was less after iv dexmedetomidine 2 µg/kg compared with the corre-
sponding group medetomidine 4 µg/kg. Arterial blood pressure stayed below reference
range during anaesthesia after iv medetomidine 0.4 µg/kg /dexmedetomidine 0.2 µg/kg
but was preserved after medetomidine 40 µg/kg /dexmedetomidine 20 µg/kg. In Study IV
after premedication with im dexmedetomidine 10 µg/kg, blood pressures stayed within
normal reference range during anaesthesia, but the dogs were bradycardic (Figures 8 and
9). Heart rate was lower and blood pressure higher in the propofol than in the
propofol/isoflurane group. Blood pressure was similar between propofol and control
(dexmedetomidine only) groups, but heart rate was lower in the latter group. Plasma lac-
tate concentration was higher in the propofol/isoflurane group than in the propofol group
during anaesthesia, and the highest values were detected in the control group. During
recovery heart rate and blood pressures were similar between all treatments. The dogs
were bradycardic (< 70 beats/minute) until the end of the recovery monitoring period (5
hours after im dexmedetomidine 10 µg/kg), but blood pressures did not decrease.
Bradycardia disappeared when free activity of the dogs was allowed. Mean heart rate was
approximately 75 beats/minute during normal sleep in these beagles (V). 
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Figure 5
Estimated end-tidal isoflurane concentration (A) and estimated difference with 95% CI between
medetomidine 0.4 µg/kg (Med) and dexmedetomidine 0.2 µg/kg (Dex) (B); between medetomidine
4 µg/kg and dexmedetomidine 2 µg/kg (C); and between medetomidine 40 µg/kg and dexmedeto-
midine 20 µg/kg (D) after iv premedication in six dogs. Anaesthesia was induced with propofol.
(Study III)
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Figure 6
Estimated heart rate (HR) (A) and estimated difference with 95% CI between medetomidine 40 µg/kg
(Med40) and dexmedetomidine 10 µg/kg (Dex10) (B); between medetomidine 40 µg/kg and
dexmedetomidine 20 µg/kg (Dex20) (C); between dexmedetomidine 10 µg/kg and dexmedetomidine
20 µg/kg (D) after iv dosing in six dogs. (Study I)
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Figure 7 
Estimated systolic blood pressure (SBP) (A) and estimated difference with 95% CI between medeto-
midine 40 µg/kg (Med40) and dexmedetomidine 10 µg/kg (Dex10) (B); between medetomidine 40
µg/kg and dexmedetomidine 20 µg/kg (Dex20) (C); between dexmedetomidine 10 µg/kg and
dexmedetomidine 20 µg/kg (D) after iv dosing in six dogs. (Study I)
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Figure 8
Estimated mean blood pressure (MBP) (A) and estimated difference with 95% CI between the
drugs in six dogs treated with isoflurane, propofol or control after premedication with im
dexmedetomidine 10 µg/kg of. Isoflurane vs propofol (B); isoflurane vs control (C); propofol vs con-
trol (D). (Study IV)
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Figure 9
Estimated heart rate (HR) (A) and estimated difference with 95% CI between the drugs in six dogs
treated with isoflurane, propofol or control after premedication with im dexmedetomidine 10 µg/kg.
Isoflurane vs propofol (B); isoflurane vs control (C); propofol vs control (D). (Study IV)
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Occasional second-degree AV-blocks were detected in dogs 4 and 6 five minutes after
administration of iv medetomidine 40 µg/kg and dexmedetomidine 20 µg/kg. Frequent
first-degree AV-blocks were seen in some dogs along with accentuated sinus arrhythmia
and sinus pauses in all dogs after iv medetomidine or dexmedetomidine (I). After admin-
istration of iv dexmedetomidine 10 µg/kg, frequent episodes of first-degree AV-block were
detected in all dogs during the next hour, and in dogs 2 and 6 a few episodes of second-
degree AV-blocks were also detected (II). In Study III, dog 4 had frequent episodes of sec-
ond-degree AV-blocks after administration of medetomidine 40 µg/kg and soon after
propofol induction, and dog 6 had occasional blocks after dexmedetomidine 2 µg/kg. First-
degree AV-blocks were frequently detected after premedication and during anaesthesia
when dogs were treated at the medetomidine 40 µg/kg /dexmedetomidine 20 µg/kg and
medetomidine 4 µg/kg /dexmedetomidine 2 µg/kg dose levels and occasionally after pre-
medication at the medetomidine 0.4 µg/kg /dexmedetomidine 0.2 µg/kg dose level. In
most Holter recordings, no VPCs were detected, the maximum frequency being two VPCs
over 24 hours. VPCs were not seen during anaesthesia or during the recovery period and
only twice during sedation. The development of second-degree AV-blocks varied from dog
to dog and were seen most frequently in dog 4, moderately in dogs 2 and 6 and only rarely
in the other dogs. The longest sinus pauses were 2.5 to 5.2 seconds long. Most of the
heart blocks were seen during the premedication period, when bradycardia was most
prominent. During the night after drug administration heart rate was similar between treat-
ments and did not differ from that seen in baseline recordings (V).
5.2.2 Respiratory effects of medetomidine and dexmedetomidine
(I-IV)
Respiratory rate and blood gas parameters were similar between medetomidine and
dexmedetomidine, and in conscious dogs they were not affected by the dose (I-III). In gen-
eral, respiratory rate, blood pHa and paO2 decreased slightly (I, II) with no change (I) or
some increase (II) in paCO2. During anaesthesia, pHa decreased more when dogs were pre-
medicated with iv medetomidine 40 µg/kg or dexmedetomidine 20 µg/kg than with the
lower premedicant dose levels, but paCO2 did not differ between treatments (III). In Study
IV, respiratory acidosis was induced by both anaesthesia methods after im dexmedetomi-
dine premedication, but paCO2 was higher in the propofol group than in the
propofol/isoflurane group during anaesthesia and the first hour of recovery. 
5.2.3 Cardiorespiratory effects of levomedetomidine (I, II)
Levomedetomidine 10 and 20 µg/kg iv had no effect on cardiovascular parameters (I). In
Study II, heart rate was lower with the infusion of the high dose of levomedetomidine than
with the low dose of levomedetomidine or the placebo treatment both before and after
dexmedetomidine administration. Diastolic blood pressure was higher with the high dose
of levomedetomidine than with the other treatments before dexmedetomidine (Figure 10).
Treatment with levomedetomidine caused no ECG abnormalities (I, II). Levomedetomidine
with or without dexmedetomidine had no effect on respiratory parameters (I, II). 
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Figure 10
Estimated diastolic blood pressure (DBP) (A) and estimated difference with 95% CI between levo-
medetomidine 25 µg/kg/h (Low Levo) and levomedetomidine 200 µg/kg/h (High Levo) (B); between
levomedetomidine 25 µg/kg/h and saline (Control) (C); between levomedetomidine 200 µg/kg/h and
saline (D) in six dogs. The dogs received dexmedetomidine 10 µg/kg iv at 60 minutes. (Study II)
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5.3 Pharmacokinetics and plasma drug concentrations
(I, II)
The mean plasma concentrations for medetomidine, dexmedetomidine and levomedeto-
midine after a single iv dose are presented in figure 11. Clearance was higher and the vol-
ume of distribution at steady-state larger with iv levomedetomidine than with iv
dexmedetomidine or racemic medetomidine, but the terminal half-lives did not differ
between the drugs. Peak sedative and analgesic effects were observed at mean (± SD) plas-
ma concentrations of 18.5 ± 4.7 ng/ml for medetomidine 40 µg/kg, 4.0 ± 4.5 ng/ml for
dexmedetomidine 20 µg/kg and 5.5 ± 1.3 ng/ml for dexmedetomidine 10 µg/kg after iv
bolus administration. The dogs were still moderately sedated at plasma concentrations of
9.5 ± 2.5 ng/ml for medetomidine 40 µg/kg, 6.2 ± 0.9 ng/ml for dexmedetomidine 20
µg/kg and 2.7 ± 0.9 ng/ml for dexmedetomidine 10 µg/kg (I). 
Administration of iv bolus dexmedetomidine 10 µg/kg to the dogs receiving levo-
medetomidine infusion resulted in an abrupt increase in the combined levomedetomidine-
dexmedetomidine concentration, which did not decrease during the subsequent hour (II).
5.4 Stress hormones (II, IV)
Levomedetomidine did not have a consistent influence on plasma catecholamine concen-
trations. After dexmedetomidine administration, the plasma adrenaline and noradrenaline
concentrations decreased (II). Propofol-isoflurane or propofol infusion anaesthesia had no
influence on plasma beta-endorphin, cortisol and noradrenaline concentrations at the end
of anaesthesia and during recovery in dexmedetomidine-premedicated dogs. Adrenaline
concentration increased more slowly during recovery when the dogs had received propo-
fol infusion as compared with dexmedetomidine sedation (IV). Baseline plasma beta-endor-
phin concentration was 13.3 ± 2.3 pmol/l.
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Figure 11
Mean plasma concentration of medetomidine (Med) 40 µg/kg; dexmedetomidine (Dex) 20 and 10
µg/kg; levomedetomidine (Levo) 20 and 10 µg/kg after iv bolus administration in six dogs. (Study I)
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6. DISCUSSION
6.1 Methodological considerations
6.1.1 Statistical and study design considerations
Six experimental beagles were used in all of the trials. The beagles were purposefully bred,
had the same background, age and breed and were kept in uniform housing and handling
conditions. As the studies were non-clinical, the common statistical methods of experi-
mental trials instead of power analysis were applied. Randomized 6 x 6 Latin square
designs were utilized to diminish variation caused by the treatment order and variation
between individuals. Accordingly, the sample size resulted in a primary outcome where sig-
nificant differences between treatments were detected.
95% confidence intervals were calculated for the differences at each time-point to re-
evaluate the power of the statistics used in some of the tests where significant differences
were not shown. This assessment suggested that use of a larger sample size (either more
beagles or more repetitions on the present dogs) might have revealed differences that here
went undetected. Clinically significant differences could not be excluded in some of the
variables showing no statistical significance.
The main investigator was unaware of whether dogs were receiving medetomidine or
dexmedetomidine, thus filling the criteria of blinding. However, in Study III, the dose level
could not be blinded, as the differences between the clinical effects of these doses were
too distinct. Moreover, in Study IV, there was no blinding between isoflurane and propo-
fol anaesthesia due to technical difficulties at the time of the study. The lack of blinding
might have affected the assessment of the level of anaesthesia. 
As haemodynamic parameters were used to evaluate the level of anaesthesia in Study
III, the lack of haemodynamic response when the highest premedication dose levels were
used may have caused a lower level of anaesthesia at this dose. The lack of a placebo
group makes it difficult to evaluate whether the lowest premedication dose level had any
clinical effects during anaesthesia. In Studies IV and V, we used dexmedetomidine alone
as a control group to evaluate the effects of anaesthesia on clinical signs and recovery in
dexmedetomidine-premedicated dogs. The use of a placebo group would have yielded a
different aspect in this study. 
In Study I, the pharmacokinetic results of iv medetomidine, dexmedetomidine and lev-
omedetomidine would have been more accurate had there been supplementary sampling
points, especially immediately after drug delivery. As the evaluation of the clinical effects
of drugs was our priority, blood sampling was kept to a minimum.
6.1.2 Assessment of analgesia and the level of anaesthesia 
We evaluated analgesia by studying flexor reflexes. In addition, the cold pressor test was
used. We wanted to apply methods that are easy to use and repeat and that avoid tissue
destruction or sensitization (wind-up) after numerous repetitions.
As pain behaviour consists of a pain sensation as well as a subjective reaction to pain
(i.e. suffering), it is beyond our available methodologies to objectively evaluate how ani-
mals experience pain. In the absence of precise tools, we are forced to use methods such
as withdrawal reflex observation, even though it is a somewhat inaccurate method for
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measuring the analgesic effect of a drug. Because flexing of the leg in response to pinch-
ing is a spinal reflex, it does not testify that the animal has had a central experience of
pain. However, in humans, a close correspondence exists between nociceptive withdraw-
al thresholds and subjective pain sensation (Page & France, 1997). The same observation
is anecdotally assumed to be applicable to veterinary patients. 
Withdrawal reflex tests are generally considered valid when α2-adrenoceptor agonist-
mediated analgesia is evaluated (Poree et al., 1998; Guo et al., 1999), as the analgesic
action of dexmedetomidine is known to mainly be spinally mediated (Kalso et al., 1991;
Hayashi et al., 1995b). It has been shown to interrupt the nociceptive pathway from the
dorsal horn of the spinal cord to the ventral root, thus reducing the spinal reflex (Kendig
et al., 1991; Savola et al., 1991b). At low doses of dexmedetomidine, a supraspinal mech-
anism may predominate (Pertovaara et al., 1991), reducing the unpleasantness of pain but
with less impact on pain threshold (Jaakola et al., 1991; Kauppila et al., 1991). Supraspinal
effects may also modulate the nociceptive flexor reflex threshold (Willer et al., 1979). As
the analgesic action of dexmedetomidine is accompanied by sedation, the degree of seda-
tion has an impact on the spinal reflexes and disturbs the assessment of pain.
The anaesthetic-sparing effect of a drug is usually studied by MAC determination using
a supramaximal stimulus and observation of gross purposeful movements. In Study III, the
anaesthesia level was defined by clinical signs and abolishment of the flexor reflex. In rats,
depression of withdrawal force correlated well with MAC determination, being abolished
at periMAC concentrations (Antunes et al., 2003; Jinks et al., 2003). However, MAC deter-
minations should be done to assess possible difference in the anaesthetic-sparing effect
between dexmedetomidine and medetomidine. In Study IV, common clinical signs were
used to define the anaesthesia level between the two different anaesthesia methods.
Adding a noxious stimulus, such as a tail clamp, might have helped to evaluate the level
of anaesthesia more accurately.
6.2 Clinical signs of sedation and analgesia
The analgesic effect of dexmedetomidine was longer lasting than that of a corresponding
dose of medetomidine, and a high dose of levomedetomidine reduced the sedative and
analgesic effects of dexmedetomidine. The levo-enantiomer may have some interaction with
the dextro-form, perhaps causing antagonism, competition at the same receptor sites or
levomedetomidine action on α1-adrenergic receptors. The α2- to α1-adrenoceptor selectiv-
ity ratio of levomedetomidine is much lower than that of dexmedetomidine (Aantaa et al.,
1993), and levomedetomidine has been reported to be able to bind to and activate α1-
adrenergic receptors (Schwinn et al, 1991). α1-adrenergic receptors can mediate behavioural
activation in states of CNS depression (Pichler & Kobinker, 1985), and activation of central
α1-adrenergic receptors have been suggested to functionally antagonize the hypnotic
responses to α2- adrenoceptor agonists (Doze et al., 1989b; Guo et al., 1991). Jansson et
al. (1998) speculated that levomedetomidine could transduce both agonistic and antago-
nistic signals through α2A-adrenergic receptors. It may act as a weak partial α2-adrenergic
agonist in systems with low receptor activity. When the receptors express high activity, it
behaves as an inverse α2-adrenergic agonist (negative antagonist) similar to atipamezole by
causing the opposite biological effect to dexmedetomidine (Jansson et al, 1998).
Dexmedetomidine changes the balance between active and inactive receptors. Thus, the
antagonizing property of levomedetomidine may become apparent, as it did in Studies I and
II, suggesting that the use of dexmedetomidine is preferable to medetomidine in dogs. 
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The similarity of the level of sedation caused by different doses of dexmedetomidine
(despite differing concentrations in plasma) in Study I suggests a ceiling effect exists that
cannot be surpassed by increasing the dose. Schwinn et al., (1991) recommended avoid-
ing high doses of dexmedetomidine, as dexmedetomidine’s ability to activate α1-adrener-
gic receptors may attenuate its α2-mediated hypnotic action. In cats, increasing the blood
concentration of dexmedetomidine beyond a certain level decreased the level of sedation,
even though the level of analgesia increased (Ansah et al., 2000). Likewise, rats showed
signs of excitement or decreased sedation after a very high dose of dexmedetomidine
(Doze et al., 1989a; Savola & Virtanen, 1991). In the present study, these signs were not
seen when the highest doses (20 µg/kg of iv dexmedetomidine and 40 µg/kg of iv medeto-
midine) were used. However, our results suggest that these doses may be unnecessarily
high for sedation in dogs, as increasing the dose above 10 µg/kg of iv dexmedetomidine
did not increase the level of sedation or analgesia; it merely resulted in longer lasting
effects. 
The cold pressor test, a method developed to assess sympathetic nervous system activ-
ity, has been used to evaluate the analgesic effect of α2-adrenergic agonist drugs in
humans (Ebert et al., 2000; Hall et al., 2000). Pain sensation to the test was decreased
even at low concentrations of dexmedetomidine, and at higher doses the deeper plane of
sedation resulted in no pain response (Ebert et al., 2000). The usefulness of the cold pres-
sor test in dogs was investigated in Study IV, but the dose of dexmedetomidine (10 µg/kg)
was apparently too high in this group of dogs. While most dogs showed minimal or no
response to cold water after dexmedetomidine, one dog resisted the test vigorously every
time. An increase in respiratory rate was generally a more sensitive parameter than changes
in cardiovascular variables for revealing production of sympathetic activity. The cold pres-
sor test might be more useful with lower doses of dexmedetomidine; however, in less
sedated dogs, a learning effect might modify physical response after repeated stimulus. 
Signs of light analgesia were already seen after 2 µg/kg of iv dexmedetomidine. Muir
et al. (1999) observed a lack of analgesic effect (measured by the clinical signs of pain)
with im medetomidine at doses of 2 and 5 µg/kg in dogs of various breeds. In our study,
the moderate sedation accompanied with the signs of light analgesia may have affected
the observable pain response. 
Our results suggest that dexmedetomidine could be more useful than medetomidine
as an analgesic in dogs, and the analgesic effects of iv dexmedetomidine are observable
at doses above 2 µg/kg.
6.3 Effects of premedicants on anaesthesia and
recovery profile
Dexmedetomidine and medetomidine reduced the requirements of propofol and isoflu-
rane dose-dependently to reach similar planes of anaesthesia. Combined mean end-tidal
isoflurane concentration for all dose levels was transiently lower after dexmedetomidine
than after medetomidine, and this finding could be attributable to the prolonged analgesic
effect of dexmedetomidine. Less selective α2-adrenergic agonist drugs are claimed to
reduce anaesthetic requirements less than dexmedetomidine, probably due to increased
α1-adrenoceptor stimulation (Hayashi & Maze, 1993). In sheep undergoing orthopaedic
surgery, dexmedetomidine had similar effects on isoflurane requirements as comparable
doses of medetomidine (Kästner et al., 2001a; Kästner et al., 2001b). Although our results
suggest that the presence of the levo-enantiomer may influence the anaesthetic-sparing
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effect of dexmedetomidine, a larger sample size is needed to prove this assumption.
The optimal dose level of iv dexmedetomidine as a premedicant was 2 µg/kg, as
intense bradycardia and hypotension were avoided during propofol/isoflurane anaesthe-
sia after this dose (III). However, the effect was short-lasting and the sedation achieved by
this dose may not consistently be adequate for healthy dogs. While the premedicants were
administered iv in Study III, the im route seems to be preferable to avoid abrupt cardio-
vascular changes and to lengthen the sedative and analgesic effects of the α2-adrenergic
agonist drug. The optimal im premedicant medetomidine dose in dogs has been suggest-
ed to be 20 µg/kg (Young et al., 1990), or between 10 and 40 µg/kg, with the lower dose
causing inconsistent and the larger dose excessive sedation for preoperative purposes
(Räihä et al., 1989). Muir et al. (1999) reported that im doses of medetomidine at or below
5 µg/kg caused excitement in some dogs of various breeds. However, in the present study,
no signs of excitement were observed in the beagles treated iv with either 4 µg/kg of
medetomidine or the equipotent dexmedetomidine dose (2 µg/kg). The discrepant results
might be explained by differences in administration methods or by only laboratory beagles
being used in our study. When determining the premedicant dose of an α2-adrenergic ago-
nist drug, the size, age, general behaviour and health status of the dog should be taken
into account to achieve the optimal dose for each patient.
The effects of α2-adrenergic agonist drugs might reduce the sensitivity of haemody-
namic variables as signs of anaesthetic depth (Erkola et al., 1994), which was demonstrated
with the use of different iv dexmedetomidine and medetomidine premedicant dose levels
in Study III. At the lowest premedicant dose level, distinct haemodynamic responses
occurred to noxious stimulus during anaesthesia. At higher premedicant doses, these
changes were rarely seen, although decreasing the dose of isoflurane resulted in signs of
awakening (movement) after pinching. Schmeling et al. (1999) reported that after
dexmedetomidine both haemodynamic and spinal movement responses are more attenu-
ated than those of the higher brain functions, such as those detected by electroen-
cephalogram.
In humans, similar (Lawrence & DeLange 1997) or even faster (Jaakola et al., 1992)
recoveries after premedication with dexmedetomidine as compared with placebo have
been described. In our studies the recoveries were delayed after high premedicant doses.
In Study IV, propofol/isoflurane anaesthesia had no additional effect on recovery while it
was delayed after propofol infusion. Contradictory, the recovery profile in humans after
propofol infusion has been similar to that after isoflurane anaesthesia when α2-agonist
premedicants have not been used (Myles et al., 2000; Godet et al., 2001), and a rapid
recovery after propofol infusion is reported in dogs (Nolan & Reid, 1993). Cardiovascular
effects of dexmedetomidine and pharmacokinetic interactions may have altered the rate
of metabolism of both dexmedetomidine and propofol (Mouton Perry et al., 1991; Bührer
et al., 1994). In humans, a low dose of dexmedetomidine reduced the propofol infusion
dose but did not affect the pharmacokinetics of propofol or recovery time after infusion
(Dutta et al., 2001). In dogs, blood systemic clearance of propofol was almost halved by
premedication with 20 µg/kg medetomidine (Hall et al., 1997). Dexmedetomidine and
levomedetomidine have been shown to be potent inhibitors of drug-metabolizing activi-
ties in vitro (Pelkonen et al., 1991; Kharasch et al., 1991, 1992), but less potent in vivo
(Pelkonen et al., 1991). While the hexobarbital sleeping time in rats was prolonged by a
high dose of levomedetomidine, a clinical dose had no effect (Pelkonen et al., 1991).
Dexmedetomidine is considered to have a low potency for inhibiting P450 enzyme func-
tion in dogs (Maze et al., 1991). However, Kharasch et al. (1992) suggested that
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dexmedetomidine might be less susceptible to drug interactions than the racemic mixture,
and thus, preferable as a premedicant. In the present study, the recovery profile after
propofol/isoflurane anaesthesia was unaffected by the premedicant drug, suggesting that
medetomidine and dexmedetomidine are equally useful as premedicants as far as unevent-
fulness of recovery is concerned. The effects of medetomidine and dexmedetomidine on
recovery after propofol infusion were not compared in this study.
6.4 Cardiorespiratory effects
The cardiorespiratory effects of dexmedetomidine were similar to the equipotent doses of
medetomidine (I, III). However, a high dose of levomedetomidine decreased heart rate,
increased blood pressure and, when combined with dexmedetomidine, enhanced brady-
cardia (II). Accordingly, it could be speculated that the presence of high concentrations of
circulating levomedetomidine molecules has a clinically unfavourable effect. The weak par-
tial α2-adrenergic action of levomedetomidine (Jansson et al., 1994), α1-adrenergic acti-
vation induced vasoconstriction, or both, may explain these findings. The bradycardic
effects of medetomidine and dexmedetomidine have also been compared in sheep and
rats, and the results suggest that medetomidine may lower heart rate more than
dexmedetomidine. Intraoperative heart rate was lower in sheep premedicated with
medetomidine than in those premedicated with an equipotent dose of dexmedetomidine,
although the isoflurane requirement did not differ (Kästner et al., 2001b). In rats, a half-
maximal bradycardic effect was obtained at a dose of 0.4 µg/kg of medetomidine, while
a dose of 0.5 µg/kg of dexmedetomidine was required to reach a similar effect (Savola &
Virtanen, 1991). In Study III, overall heart rate was higher with the middle dose of medeto-
midine than with the corresponding dose of dexmedetomidine during isoflurane anaes-
thesia. This could be due to anaesthetic-induced changes, as isoflurane concentration tend-
ed to be higher with medetomidine 4 µg/kg than with dexmedetomidine 2 µg/kg.
The additional cardiovascular effects of the small doses of anaesthetic drugs were min-
imal when compared to the highest doses of medetomidine or dexmedetomidine alone.
When blood level of dexmedetomidine is sufficiently high, peripheral α2B-adrenoceptors
are activated, causing vasoconstriction and consequently blood pressure increases (Link et
al., 1996). The vasoconstrictive and sympatholytic effects of a high dose of dexmedeto-
midine may predominate and counteract the vasodilatation caused by isoflurane, thus
inducing bradycardia and preventing hypotension during anaesthesia (Bloor et al., 1992b).
Bloor et al. (1992b) have suggested that the vasoconstrictive effect of an α2-adrenocep-
tor agonist drug might be more prominent and longer lasting in dogs than in humans.
Moreover, as the doses of dexmedetomidine administered to humans are usually much
smaller than those given to dogs, the predominant effect of dexmedetomidine in humans
is a centrally mediated decrease in blood pressure, while in dogs initial hypertension is more
commonly seen. 
In awake humans blood pressure has been shown to decrease at a plasma dexmedeto-
midine concentration below 1.2 ng/ml, which was achieved by iv infusion of the drug
(Ebert et al., 2000). In Study I, diastolic blood pressure had decreased to normal levels at
plasma dexmedetomidine concentrations of 4 to 9 ng/ml, but the dogs were still not
hypotensive at a dexmedetomidine concentration of approximately 1 ng/ml two hours after
drug administration. Similarly, after receiving im dexmedetomidine 10 µg/kg, blood pres-
sure stayed within reference range during the three-hour recovery despite continuing
bradycardia (IV). However, when the lowest iv premedicant doses (medetomidine 0.4 µg/kg
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and dexmedetomidine 0.2 µg/kg) were used before propofol/isoflurane anaesthesia (III),
the dogs were more hypotensive than usually reported under a light level of isoflurane
anaesthesia only (Klide, 1976; Mutoh et al., 1997). The induction dose of propofol may
have decreased blood pressure further, but this result can also suggest that at these low
premedicant doses central effects of dexmedetomidine predominated over peripheral
effects. Hypotensive effects have been reported to exceed the vasoconstrictive effects at
bolus iv doses below 1 µg/kg of dexmedetomidine in anaesthetized dogs (Lawrence et al.,
1996b). In the current study, premedication with iv 2 µg/kg of dexmedetomidine or iv 4
µg/kg of medetomidine before propofol/isoflurane anaesthesia resulted in the most stable
cardiovascular effects when compared with the higher and lower dose levels.
In dogs, propofol is claimed to maintain arterial blood pressure better than isoflurane
(Keegan & Greene, 1993; Deryck et al., 1996) with a similar (Deryck et al., 1996) or low-
er (Keegan & Greene, 1993) heart rate. When medetomidine is combined with propofol
infusion, variable cardiovascular effects have been reported (Vainio, 1991; Lagerweij et al.,
1993; Hammond & England, 1994; Hall et al., 1997). In Study IV, blood pressure was sim-
ilar for propofol infusion and controls (dexmedetomidine only), which implies that the vaso-
constrictive effects of dexmedetomidine predominated and prevented hypotension. Blood
pressure stayed within normal reference range even during isoflurane, although the dogs
were not surgically stimulated. Even though blood pressure was similar, heart rate was con-
sistently higher during propofol infusion compared with dexmedetomidine at the same
time. This finding may at least partially be explained by the hypercapnia induced by propo-
fol (Taylor, 1998; Mas et al., 2000). 
No differences were present between medetomidine and dexmedetomidine in ECG
findings, and levomedetomidine showed no effects on heart rhythm. VPCs were not
detected in intermittent ECG recordings or in most Holter recordings, but the low number
of dogs used may partly explain the lack of findings. In healthy non-anaesthetized dogs,
VPCs do exist but are found infrequently (Hall et al., 1991; Ulloa et al., 1995; Meurs et al.,
2001). In a Holter study of 228 healthy beagles, 49 showed ventricular ectopy, most hav-
ing less than nine single VPCs over a 24-hour period (Ulloa et al., 1995). In the same study,
second-degree AV-blocks were sporadically encountered. In severely diseased canine
patients undergoing splenectomy, a high incidence of perioperative VPC and ventricular
tachycardia was revealed by Holter analysis (Marino et al., 1994). In a study of 50 canine
patients free of cardiac diseases, VPCs and atrioventricular conduction defects were the
most frequently observed arrhythmias during the recovery period. Acepromazine, pethi-
dine and halothane were the drugs most commonly included in the anaesthetic regimen
in this earlier study, and the type of surgical or diagnostic procedure did not influence the
incidence of arrhythmias (Buss et al., 1982). Reports on the effects of α2-adrenoceptor
agonists on ventricular arrhythmias are inconsistent. The stimulation of α1-adrenoceptors
may cause ventricular arrhythmias (Hayashi et al., 1988) and xylazine, a less α2-specific
drug than dexmedetomidine, has been reported to decrease the arrhythmogenic dose of
adrenaline in anaesthetized dogs (Tranquilli et al., 1986, 1988). In later studies, however,
xylazine or medetomidine did not enhance arrhythmogenicity in either halothane- (Lemke
et al., 1993; Pettifer et al., 1996) or isoflurane-anaesthetized dogs (Lemke et al., 1993).
Dexmedetomidine has been shown to prevent adrenaline-induced arrhythmias in
halothane-anaesthetized dogs (Hayashi et al., 1991). Hayashi et al. (1993) and Kamibayashi
et al. (1995b) have suggested that this effect is due to the action of dexmedetomidine on
imidazoline-preferring receptors in the CNS. Dexmedetomidine has been demonstrated to
reduce the oxygen deficiency of the ischaemic myocardium in anaesthetized dogs
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(Roekaerts et al., 1996). In human patients undergoing vascular surgery, dexmedetomidine
administration reduced the haemodynamic responses to perioperative stress (Talke et al.,
1995). The low frequency of VPCs detected in Study V is in accordance with these earlier
reports.
The occurrence of AV-blocks was dose-dependent, variable between dogs and no dif-
ferences could be shown between dexmedetomidine and medetomidine. The AV-blocks
were mostly seen soon after administration of the drugs, when bradycardia was most
prominent. During anaesthesia the AV-blocks decreased or vanished as heart rate
increased, but they sometimes reappeared during the early recovery period. The length of
sinus pauses during treatments was similar to that reported earlier in non-anaesthetized
dogs (Hall et al., 1991), and the pauses coincided with bradycardia. The AV-blocks and
sinus pauses detected during these studies were not considered to be clinically significant.
The respiratory parameters stayed within normal physiological values even during pro-
found sedation, and levomedetomidine had no respiratory effects alone or combined with
dexmedetomidine (I, II). During anaesthesia hypoventilation was seen (III, IV). The degree
of hypercapnia was similar between medetomidine and dexmedetomidine and independ-
ent of the premedicant dose, contradictory to some previous studies in dogs. Nguyen et
al. (1992) have reported signs of improved ventilation after very high dexmedetomidine
doses. Combination of dexmedetomidine and isoflurane has resulted in less respiratory
depression than isoflurane alone (Bloor et al., 1989; Nguyen et al., 1992). However, the
present results suggest that increasing the premedicant dose may not offer any respirato-
ry benefit even though the delivery of isoflurane can be decreased (III). Dexmedetomidine
combined with propofol infusion resulted in more profound hypoventilation and respira-
tory acidosis than dexmedetomidine and propofol/isoflurane (IV). In earlier propofol infu-
sion studies, dogs were either ventilated to normocapnia (Keegan & Greene, 1993) or
breathed room air, showing only moderate increases in paCO2 with occasional hypoxemia
(Vainio, 1991; Hall et al., 1997). Hyperoxia has been reported to impair ventilation (Gaudy
et al., 1988), and the delivery of pure oxygen may partly explain the more severe respira-
tory depression shown earlier. As the dogs with the highest paCO2 values showed signs of
light anaesthesia, the hypoventilation may have been overlooked if end-tidal CO2 had not
been monitored. Thus, isoflurane may be a safer choice than propofol as an anaesthetic
in dexmedetomidine-premedicated, spontaneously ventilating dogs.
In Study III, the combination of iv medetomidine 40 µg/kg or dexmedetomidine 20
µg/kg with propofol/isoflurane induced slight metabolic acidosis. Impaired tissue perfusion
may explain this finding, despite saturation of arterial haemoglobin being adequate.
However, arterial lactate concentrations were unchanged after iv dexmedetomidine 10
µg/kg in dogs (Lawrence et al., 1996a), and likewise in Study IV blood lactate values after
10 µg/kg of dexmedetomidine were within the reference range reported for healthy con-
scious dogs (Hughes et al., 1999). The lower lactate values detected during propofol infu-
sion than during propofol/isoflurane anaesthesia suggests better tissue perfusion with
propofol, which might be caused by the more severe hypercapnia in this group (IV). 
While these studies showed no clinically significant cardiorespiratory differences
between medetomidine and dexmedetomidine, the latter may be more suitable in dogs
due to the bradycardic effects of levomedetomidine. When dexmedetomidine is used as a
premedicant, a dose level of 2 µg/kg is suggested to achieve stable cardiovascular effects,
and maintenance of anaesthesia with isoflurane may depress ventilation less than propo-
fol. 
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6.5 Pharmacokinetics
Medetomidine is metabolized mainly by hepatic hydroxylation in dogs (Salonen, 1992),
while in humans hepatic glucuronidation of dexmedetomidine and levomedetomidine is
more efficient than in dogs. In dog liver microsomes, glucuronidation of levomedetomi-
dine was eight times more efficient than that of dexmedetomidine (Kaivosaari et al., 2002).
In Study I, clearance of levomedetomidine was more rapid than that of dexmedetomidine
or medetomidine, This could be caused by partly divergent metabolic pathways for these
enantiomers. Furthermore, dexmedetomidine may reduce its own elimination rate dose-
dependently via its haemodynamic effects (Salonen et al., 1995). In humans, the decrease
in cardiac output with increasing plasma concentrations of dexmedetomidine resulted in
a corresponding decrease in dexmedetomidine elimination clearance (Dutta et al., 2000).
The circulatory effects of dexmedetomidine probably also account for the larger distribu-
tion volume with levomedetomidine than with dexmedetomidine and medetomidine in
Study I. Dexmedetomidine has been shown to modify thiopental body disposition in a sim-
ilar way (Bührer et al., 1994). The haemodynamic effects of dexmedetomidine most likely
explain the high combined plasma levomedetomidine and dexmedetomidine concentra-
tions during infusion of levomedetomidine in Study II. Accordingly, when high doses of
medetomidine are used, the plasma levomedetomidine concentration and even the clini-
cal effect of levomedetomidine may be unexpectedly elevated.
6.6 Stress hormones
Medetomidine has been demonstrated to control the stress response induced by anaes-
thesia and surgery during the perioperative period in dogs (Benson et al., 2000; Ko et al.,
2000; Väisänen et al., 2002). In Study IV, while recovery was faster after isoflurane than
after propofol infusion, no signs of excitation or anxiety were seen, and the endocrine
stress response was mild and similar between treatments. Dexmedetomidine apparently
concealed possible stress effects of anaesthesia during recovery. The delayed increase in
adrenaline concentration after propofol infusion is most likely due to the slower recovery
in this group, when compared with the other treatments. The baseline beta-endorphin lev-
el in these dogs was comparable with the concentration detected after dexmedetomidine
premedication and was shown to be unaffected by propofol or propofol/isoflurane anaes-
thesia (IV). In humans, a low level of beta-endorphin is considered a sign of stress-free
anaesthesia (Lehtinen et al., 1984). In horses, anaesthesia alone and especially hypoxic
anaesthesia has been revealed to increase plasma beta-endorphin levels (Taylor et al.,
2000). In dogs undergoing ovariohysterectomy, while the concentration of beta-endorphin
increased during surgery, it was similar in dogs receiving either medetomidine/opioid or
acepromazine/opioid premedication (Väisänen et al., 2002). In our studies, medetomidine
and dexmedetomidine had similar effects on stress response in dogs, and anaesthesia did
not modify the effect.
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7. CONCLUSIONS
Dexmedetomidine was at least as safe and effective as the corresponding dose of medeto-
midine as a sedative, analgesic and premedicant in laboratory beagles. The pharmacoki-
netics of dexmedetomidine and racemic medetomidine were similar, but clearance of levo-
medetomidine was more rapid than that of the other drugs. Levomedetomidine did not
cause any observable behavioural effects in conscious dogs. However, it did reduce the
sedative and analgesic effects of dexmedetomidine and intensified bradycardia, suggest-
ing that use of dexmedetomidine might be preferable to medetomidine in dogs. The dose
level of 2 µg/kg of dexmedetomidine resulted in most stable cardiovascular effects when
used as a premedication before propofol/isoflurane anaesthesia. After dexmedetomidine
premedication, propofol/isoflurane anaesthesia was considered more suitable than propo-
fol infusion due to a milder degree of respiratory depression and faster recovery. The cold
pressor test produced variable responses among the dogs and was not a reliable stress
stimulus with the dexmedetomidine dose used. In beagles treated with dexmedetomidine
alone or combined with propofol infusion or propofol/isoflurane, ventricular arrhythmias
were detected no more frequently than in healthy non-anaesthetized dogs.
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